<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26924986</article-id>
<article-id pub-id-type="pmc">4757672</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2016.00030</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological Diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Rižner</surname>
<given-names>Tea Lanišnik</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/44103/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff>
<institution>Faculty of Medicine, Institute of Biochemistry, University of Ljubljana</institution>
<country>Ljubljana, Slovenia</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Ajay Sharma, Chapman University School of Pharmacy, USA</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Chris J. Van Koppen, ElexoPharm GmbH, Germany; Partha Krishnamurthy, University of Kansas Medical Center, USA</p>
</fn>
<corresp id="fn001">*Correspondence: Tea Lanišnik Rižner <email xlink:type="simple">tea.lanisnik-rizner@mf.uni-lj.si</email></corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>7</volume>
<elocation-id>30</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>11</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>03</day>
<month>2</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2016 Rižner.</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>Rižner</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Gynecological diseases such as endometriosis, adenomyosis and uterine fibroids, and gynecological cancers including endometrial cancer and ovarian cancer, affect a large proportion of women. These diseases are estrogen dependent, and their progression often depends on local estrogen formation. In peripheral tissues, estrogens can be formed from the inactive precursors dehydroepiandrosterone sulfate and estrone sulfate. Sulfatase and sulfotransferases have pivotal roles in these processes, where sulfatase hydrolyzes estrone sulfate to estrone, and dehydroepiandrosterone sulfate to dehydroepiandrosterone, and sulfotransferases catalyze the reverse reactions. Further activation of estrone to the most potent estrogen, estradiol, is catalyzed by 17-ketosteroid reductases, while estradiol can also be formed from dehydroepiandrosterone by the sequential actions of 3β-hydroxysteroid dehydrogenase-Δ<sup>4</sup>-isomerase, aromatase, and 17-ketosteroid reductase. This review introduces the sulfatase and sulfotransferase enzymes, in terms of their structures and reaction mechanisms, and the regulation and different transcripts of their genes, together with the importance of their currently known single nucleotide polymorphisms. Data on expression of sulfatase and sulfotransferases in gynecological diseases are also reviewed. There are often unchanged mRNA and protein levels in diseased tissue, with higher sulfatase activities in cancerous endometrium, ovarian cancer cell lines, and adenomyosis. This can be indicative of a disturbed balance between the sulfatase and sulfotransferases enzymes, defining the potential for sulfatase as a drug target for treatment of gynecological diseases. Finally, clinical trials with sulfatase inhibitors are discussed, where two inhibitors have already concluded phase II trials, although so far with no convincing clinical outcomes for patients with endometrial cancer and endometriosis.</p>
</abstract>
<kwd-group>
<kwd>endometrial cancer</kwd>
<kwd>endometriosis</kwd>
<kwd>adenomyosis</kwd>
<kwd>uterine fibroids</kwd>
<kwd>estrogen formation</kwd>
<kwd>estrone sulfate</kwd>
<kwd>dehydroepiandrosterone sulfate</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">Javna Agencija za Raziskovalno Dejavnost RS<named-content content-type="fundref-id">10.13039/501100004329</named-content></funding-source>
<award-id rid="cn001">J3-5510</award-id>
<award-id rid="cn001">J3-6799</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="3"></fig-count>
<table-count count="7"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="151"></ref-count>
<page-count count="16"></page-count>
<word-count count="13767"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Steroid sulfatase</title>
<p>The formation and hydrolysis of steroid sulfates by the steroid sulfotransferase (SULT) and steroid sulfatase (STS) enzymes, respectively, represent important mechanisms in the regulation of the biological activities of many steroid hormones (Purohit et al., <xref ref-type="bibr" rid="B107">1998</xref>). STS (E.C. 3.1.6.2.) hydrolyzes estrone sulfate (E1-S) and dehydroepiandrosterone sulfate (DHEA-S) to E1 and DHEA, respectively (Figure <xref ref-type="fig" rid="F1">1</xref>), as well as cholesterol sulfate and pregnenolone sulfate to their corresponding unconjugated forms. The sulfatase protein family includes 17 different human sulfatases, where only STS act on steroid sulfates (Mueller et al., <xref ref-type="bibr" rid="B90">2015</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p><bold>The roles of the STS and SULT enzymes in local estrogen biosynthesis</bold>. Synthesis of E2 from DHEA-S by the action of steroid sulfatase (STS), 3β-hydroxysteroid dehydrogenase-Δ<sup>4</sup>-isomerase (HSD3B1, HSD3B2), aromatase (CYP19A1) and 17-ketosteroid reductase (HSD17B1) or aldo-keto reductase 1C3 (AKR1C3) and CYP19A1; and from E1-S by the action of STS and HSD17B1. Sulfotransferases 2A1 (SULT2A1) and SULT2B1 catalyze the conjugation of DHEA, and SULT1E1 catalyzes the conjugation of E1. Oxidation of E2 to E1 is catalyzed by HSD17B2.</p>
</caption>
<graphic xlink:href="fphar-07-00030-g0001"></graphic>
</fig>
<p>STS has been found in the membranes of the endoplasmic reticulum and was purified from human placenta (Hernandez-Guzman et al., <xref ref-type="bibr" rid="B51">2001</xref>). It is a monomer with a molecular mass of 63 kDa, an N-terminal signal peptide of 21–23 amino acids, and four potential and two functional (i.e., Asn47, Asn259) glycosylation sites (Reed et al., <xref ref-type="bibr" rid="B112">2005</xref>). Purified STS has been crystallized, and its structure has been defined at 2.6-Å resolution (pdb code 1P49; Hernandez-Guzman et al., <xref ref-type="bibr" rid="B51">2001</xref>, <xref ref-type="bibr" rid="B52">2003</xref>). The three-dimensional structure of STS shows a globular polar domain with the catalytic site, and the putative transmembrane domain that consists of two antiparallel hydrophobic alpha helices (Hernandez-Guzman et al., <xref ref-type="bibr" rid="B52">2003</xref>) (Figure <xref ref-type="fig" rid="F2">2A</xref>). STS includes Ca<sup>2+</sup> as a cofactor and 10 catalytically important amino acid residues: Arg35, Arg36, ARG78, Arg342, Lys134, Lys368, His136, His290, Gln343 and a formylglycine (FGly75). This posttranslational modification of Cys75 to FGly75 is mediated by the FGly-generating enzyme encoded by <italic>sulfatase-modifying factor 1</italic> (Preusser-Kunze et al., <xref ref-type="bibr" rid="B104">2005</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p><bold>Tertiary structure and reaction mechanism of the human STS enzyme. (A)</bold> Structure of the human STS enzyme (pdb 1P49), with transmembrane helices and the globular domain with the active site with cofactor Ca<sup>2+</sup>. <bold>(B)</bold> The reaction mechanism of the STS enzyme and the roles of the catalytical amino-acid residues His136, Lys134, His290, and Lys368. FGly, formylglycine; HFGly, hydroxyformylglycine; HFGlyS, hydroxyformylglycine sulfate. The scheme was adopted from Ghosh (<xref ref-type="bibr" rid="B45">2007</xref>).</p>
</caption>
<graphic xlink:href="fphar-07-00030-g0002"></graphic>
</fig>
<p>STS catalyzes the hydrolysis of the sulfate moiety in a four-step mechanism. According to Ghosh (<xref ref-type="bibr" rid="B45">2007</xref>), these steps comprise: (1) activation of FGly75 by a water molecule; (2) nucleophilic attack of hydroxy-FGly on the sulfur atom of the substrate (i.e., E1-S, DHEA-S), which is facilitated by Ca<sup>2+</sup>; (3) release of the free hydroxy-product (i.e., E1, DHEA); and finally (4) release of <inline-formula><mml:math id="M1"><mml:msubsup><mml:mtext>HSO</mml:mtext><mml:mrow><mml:mn>4</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo></mml:mrow></mml:msubsup></mml:math></inline-formula> and regeneration of FGly (Figure <xref ref-type="fig" rid="F2">2B</xref>). As a sulfate moiety covalently linked to hydroxy-FGly has been observed in the crystal structure of STS, this suggests that the sulfated form of hydroxy-FGly is the resting state for human STS (Ghosh, <xref ref-type="bibr" rid="B45">2007</xref>). Kinetics characterization has revealed that purified STS can hydrolyze DHEA-S and E1-S with μM Km values (Hernandez-Guzman et al., <xref ref-type="bibr" rid="B51">2001</xref>; Table <xref ref-type="table" rid="T1">1</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p><bold>Kinetics characteristics of the STS and SULT enzymes</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Enzyme</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Substrate</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>K<sub>m</sub></bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>v<sub>max</sub></bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>v<sub>max</sub>/K<sub>m</sub></bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Ki</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">STS</td>
<td align="left" colspan="1" rowspan="1" valign="top">DHEA-S</td>
<td align="center" colspan="1" rowspan="1" valign="top">9.6 μM</td>
<td align="center" colspan="1" rowspan="1" valign="top">113.4 μmol/h/mg</td>
<td align="left" colspan="1" rowspan="1" valign="top">11.9</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Hernandez-Guzman et al., <xref ref-type="bibr" rid="B51">2001</xref><xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">E1-S</td>
<td align="center" colspan="1" rowspan="1" valign="top">72.8 μM</td>
<td align="center" colspan="1" rowspan="1" valign="top">573 μmol/h/mg</td>
<td align="left" colspan="1" rowspan="1" valign="top">7.9</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Hernandez-Guzman et al., <xref ref-type="bibr" rid="B51">2001</xref><xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SULT1E1</td>
<td align="left" colspan="1" rowspan="1" valign="top">E1</td>
<td align="center" colspan="1" rowspan="1" valign="top">110 ± 100 nM</td>
<td align="center" colspan="1" rowspan="1" valign="top">4.1 ± 0.1 nmol/h/mg</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.04</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Adjei et al., <xref ref-type="bibr" rid="B3">2003</xref><xref ref-type="table-fn" rid="TN2"><sup>b</sup></xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">E2</td>
<td align="center" colspan="1" rowspan="1" valign="top">29 ±10 nM</td>
<td align="center" colspan="1" rowspan="1" valign="top">6.9 ± 0.1 nmol/h/mg</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.24</td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Adjei et al., <xref ref-type="bibr" rid="B3">2003</xref><xref ref-type="table-fn" rid="TN2"><sup>b</sup></xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">SULT2A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">DHEA</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.5 ± 0.7 μM</td>
<td align="center" colspan="1" rowspan="1" valign="top">13.6 ± 2.5 μmol/h/mg</td>
<td align="left" colspan="1" rowspan="1" valign="top">5.4</td>
<td align="center" colspan="1" rowspan="1" valign="top">6.1 μM</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lu et al., <xref ref-type="bibr" rid="B76">2008</xref><xref ref-type="table-fn" rid="TN2"><sup>b</sup></xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">SULT2B1a<xref ref-type="table-fn" rid="TN3"><sup>*</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">DHEA</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.3 ± 0.2 μM</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.3 ± 0.01 μmol/h/mg</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.13</td>
<td align="center" colspan="1" rowspan="1" valign="top">48 μM</td>
<td align="left" colspan="1" rowspan="1" valign="top">Geese and Raftogianis, <xref ref-type="bibr" rid="B43">2001</xref><xref ref-type="table-fn" rid="TN2"><sup>b</sup></xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SULT2B1b<xref ref-type="table-fn" rid="TN3"><sup>*</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">DHEA</td>
<td align="center" colspan="1" rowspan="1" valign="top">4.4 ± 0.6 μM</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.1 ± 0.01 μmol/h/mg</td>
<td align="left" colspan="1" rowspan="1" valign="top">0.02</td>
<td align="center" colspan="1" rowspan="1" valign="top">22 μM</td>
<td align="left" colspan="1" rowspan="1" valign="top">Geese and Raftogianis, <xref ref-type="bibr" rid="B43">2001</xref><xref ref-type="table-fn" rid="TN2"><sup>b</sup></xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TN1">
<label>a</label>
<p><italic>Purified STS from human placenta</italic>.</p>
</fn>
<fn id="TN2">
<label>b</label>
<p><italic>Purified recombinant human enzymes, mean ± SEM values are shown</italic>;</p>
</fn>
<fn id="TN3">
<label>*</label>
<p><italic>SULT2B1a and SULT2B1b are two isoforms</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The <italic>STS</italic> gene has been localized to the X chromosome (Xp22.31), and it spans 146 kb, includes 10 exons, and encodes a protein of 583 amino acids (Reed et al., <xref ref-type="bibr" rid="B112">2005</xref>). Although eight tissue-specific <italic>STS</italic> transcripts have been identified (Nardi et al., <xref ref-type="bibr" rid="B93">2009</xref>), only six are currently included in the gene database: isozyme S, and variants X1 to X5 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gene">http://www.ncbi.nlm.nih.gov/gene</ext-link>). <italic>STS</italic> transcripts have 235 coding genetic variants (cSNPs) in the db SNP database (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP">http://www.ncbi.nlm.nih.gov/SNP</ext-link>; September 2015), although only one of these cSNPs, Val307Ile, has a minor allele frequency (MAF) &gt;0.01 (0.0172) (Table <xref ref-type="table" rid="T2">2</xref>). SNPs have been reported in the promoter region and in introns and exons of the <italic>STS</italic> gene (Brookes et al., <xref ref-type="bibr" rid="B11">2010</xref>; Matsumoto et al., <xref ref-type="bibr" rid="B83">2010</xref>, <xref ref-type="bibr" rid="B84">2013</xref>). Seven SNPs have been identified in the Japanese population, including one SNP in the 5′-untranslated region (155G&gt;A), five in the 5′-flanking region, and one cSNP, Val476Met, with a frequency of 0.014 (Matsumoto et al., <xref ref-type="bibr" rid="B83">2010</xref>). For three specific SNPs, functional analysis has revealed significantly decreased (155A) and increased (−2837A, −1588C) transcriptional activities in a reporter gene assay in MCF7 cells, but showed no effects at the protein and DHEAS STS activity levels for Val476Met variant (Matsumoto et al., <xref ref-type="bibr" rid="B84">2013</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p><bold>Different transcripts and genetic variants of the <italic>STS</italic> and <italic>SULT</italic> genes</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr style="border-bottom: thin solid #000000;">
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Transcript</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Size</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Protein</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>gSNP</bold>
</th>
<th align="left" colspan="3" rowspan="1" valign="top">
<bold>cSNP</bold>
</th>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>ID</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>information</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>(bp)</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>(aa)</bold>
</th>
<th colspan="1" rowspan="1"></th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Total</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>SYN</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top"><bold>MAF</bold> &gt;<bold>0.01</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">STS</td>
<td align="left" colspan="1" rowspan="1" valign="top">412</td>
<td align="left" colspan="1" rowspan="1" valign="top">Isozyme SNM_000351.4</td>
<td align="center" colspan="1" rowspan="1" valign="top">6377</td>
<td align="center" colspan="1" rowspan="1" valign="top">583</td>
<td align="center" colspan="1" rowspan="1" valign="top">4838</td>
<td align="center" colspan="1" rowspan="1" valign="top">231</td>
<td align="center" colspan="1" rowspan="1" valign="top">93</td>
<td align="left" colspan="1" rowspan="1" valign="top">Val307Ile, 0.0172</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Variant X5XM_011545518</td>
<td align="center" colspan="1" rowspan="1" valign="top">6340</td>
<td align="center" colspan="1" rowspan="1" valign="top">578</td>
<td align="center" colspan="1" rowspan="1" valign="top">3772</td>
<td align="center" colspan="1" rowspan="1" valign="top">231</td>
<td align="center" colspan="1" rowspan="1" valign="top">93</td>
<td align="left" colspan="1" rowspan="1" valign="top">Val307Ile, 0.0172</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Variant X4XM_011545517</td>
<td align="center" colspan="1" rowspan="1" valign="top">6215</td>
<td align="center" colspan="1" rowspan="1" valign="top">578</td>
<td align="center" colspan="1" rowspan="1" valign="top">3782</td>
<td align="center" colspan="1" rowspan="1" valign="top">231</td>
<td align="center" colspan="1" rowspan="1" valign="top">93</td>
<td align="left" colspan="1" rowspan="1" valign="top">Val307Ile, 0.0172</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Variant X3XM_011545516</td>
<td align="center" colspan="1" rowspan="1" valign="top">6662</td>
<td align="center" colspan="1" rowspan="1" valign="top">590</td>
<td align="center" colspan="1" rowspan="1" valign="top">7324</td>
<td align="center" colspan="1" rowspan="1" valign="top">232</td>
<td align="center" colspan="1" rowspan="1" valign="top">93</td>
<td align="left" colspan="1" rowspan="1" valign="top">Val307Ile, 0.0172</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Variant X2XM_011545515</td>
<td align="center" colspan="1" rowspan="1" valign="top">7336</td>
<td align="center" colspan="1" rowspan="1" valign="top">590</td>
<td align="center" colspan="1" rowspan="1" valign="top">7365</td>
<td align="center" colspan="1" rowspan="1" valign="top">235</td>
<td align="center" colspan="1" rowspan="1" valign="top">93</td>
<td align="left" colspan="1" rowspan="1" valign="top">Val307Ile, 0.0172</td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Variant X1XM_005274511</td>
<td align="center" colspan="1" rowspan="1" valign="top">6441</td>
<td align="center" colspan="1" rowspan="1" valign="top">723</td>
<td align="center" colspan="1" rowspan="1" valign="top">7318</td>
<td align="center" colspan="1" rowspan="1" valign="top">232</td>
<td align="center" colspan="1" rowspan="1" valign="top">93</td>
<td align="left" colspan="1" rowspan="1" valign="top">Val307Ile, 0.0172</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SULT1E1</td>
<td align="left" colspan="1" rowspan="1" valign="top">6783</td>
<td align="left" colspan="1" rowspan="1" valign="top">Variant X2XM_011532210</td>
<td align="center" colspan="1" rowspan="1" valign="top">723</td>
<td align="center" colspan="1" rowspan="1" valign="top">181</td>
<td align="center" colspan="1" rowspan="1" valign="top">911</td>
<td align="center" colspan="1" rowspan="1" valign="top">88</td>
<td align="center" colspan="1" rowspan="1" valign="top">23</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Variant X1XM_011532209</td>
<td align="center" colspan="1" rowspan="1" valign="top">1697</td>
<td align="center" colspan="1" rowspan="1" valign="top">294</td>
<td align="center" colspan="1" rowspan="1" valign="top">1337</td>
<td align="center" colspan="1" rowspan="1" valign="top">156</td>
<td align="center" colspan="1" rowspan="1" valign="top">42</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">NM_005420</td>
<td align="center" colspan="1" rowspan="1" valign="top">1805</td>
<td align="center" colspan="1" rowspan="1" valign="top">294</td>
<td align="center" colspan="1" rowspan="1" valign="top">1300</td>
<td align="center" colspan="1" rowspan="1" valign="top">156</td>
<td align="center" colspan="1" rowspan="1" valign="top">42</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">SULT2A1</td>
<td align="left" colspan="1" rowspan="1" valign="top">6822</td>
<td align="left" colspan="1" rowspan="1" valign="top">NM_003167</td>
<td align="center" colspan="1" rowspan="1" valign="top">1987</td>
<td align="center" colspan="1" rowspan="1" valign="top">285</td>
<td align="center" colspan="1" rowspan="1" valign="top">1207</td>
<td align="center" colspan="1" rowspan="1" valign="top">163</td>
<td align="center" colspan="1" rowspan="1" valign="top">48</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ala63Pro, 0.0240<break></break> Ala261Thr, 0.0407</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">SULT2B1</td>
<td align="left" colspan="1" rowspan="1" valign="top">6820</td>
<td align="left" colspan="1" rowspan="1" valign="top">Variant 2NM_177973</td>
<td align="center" colspan="1" rowspan="1" valign="top">1228</td>
<td align="center" colspan="1" rowspan="1" valign="top">365</td>
<td align="center" colspan="1" rowspan="1" valign="top">3190</td>
<td align="center" colspan="1" rowspan="1" valign="top">231</td>
<td align="center" colspan="1" rowspan="1" valign="top">88</td>
<td align="left" colspan="1" rowspan="1" valign="top">Arg33Gln, 0.0178</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Variant X1XM_005259182</td>
<td align="center" colspan="1" rowspan="1" valign="top">802</td>
<td align="center" colspan="1" rowspan="1" valign="top">221</td>
<td align="center" colspan="1" rowspan="1" valign="top">935</td>
<td align="center" colspan="1" rowspan="1" valign="top">153</td>
<td align="center" colspan="1" rowspan="1" valign="top">57</td>
<td align="left" colspan="1" rowspan="1" valign="top">–</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Variant 1 NM_004605</td>
<td align="center" colspan="1" rowspan="1" valign="top">1281</td>
<td align="center" colspan="1" rowspan="1" valign="top">350</td>
<td align="center" colspan="1" rowspan="1" valign="top">1707</td>
<td align="center" colspan="1" rowspan="1" valign="top">220</td>
<td align="center" colspan="1" rowspan="1" valign="top">82</td>
<td align="left" colspan="1" rowspan="1" valign="top">Arg18Gln, 0.0178</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>gSNP, SNP in gene region; cSNP, SNP within coding region; SYN, synonymous; MAF, minor allele frequency; data from Gene and SNP databases (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gene">http://www.ncbi.nlm.nih.gov/gene</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP">http://www.ncbi.nlm.nih.gov/SNP</ext-link>); as of September 2015</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>The loss of STS activity due to <italic>STS</italic> gene deletion or point mutations results in X-linked ichthyosis, a genetic skin disorder that affects 1 in 2000 to 1 in 6000 males and is characterized by typical scaling of the skin epidermis (Gelmetti and Ruggero, <xref ref-type="bibr" rid="B44">2002</xref>). Interestingly, deletions and mutations have been identified mainly in the regions from 7 to 10 exon, which encodes the C-terminal substrate binding part (Gelmetti and Ruggero, <xref ref-type="bibr" rid="B44">2002</xref>). This disease results from the inability to liberate cholesterol from cholesterol sulfate, and it affects the incorporation of cholesterol sulfate in the stratum corneum. It is associated with epidermal hyperplasia and the formation of additional layers of corneocytes, which leads to unacceptable sloughing of the skin epidermis (Maltais and Poirier, <xref ref-type="bibr" rid="B82">2011</xref>; Elias et al., <xref ref-type="bibr" rid="B28">2014</xref>). Kent et al. reported that boys with this genetic disorder have a significantly increased risk of attention deficit hyperactivity disorder and autism (Kent et al., <xref ref-type="bibr" rid="B64">2008</xref>). Interestingly, associations between this disorder and several SNPs within the <italic>STS</italic> gene were also reported (Brookes et al., <xref ref-type="bibr" rid="B11">2010</xref>), where the SNP rs12861247 was significantly associated with lower <italic>STS</italic> expression. In contrast to these studies, Stergiakouli et al. did not confirm these associations, although they observed associations between the SNP rs17268988 and symptoms of inattention (Stergiakouli et al., <xref ref-type="bibr" rid="B130">2011</xref>).</p>
<p>STS is ubiquitously expressed, with its highest protein levels in placenta, and lower levels in breast, skin, liver, lung, ovary, adrenal gland, endometrium, brain, and some other tissues. The tissue levels vary across physiological and pathophysiological conditions, but our current understanding of the regulation of <italic>STS</italic> expression is still very limited (Nardi et al., <xref ref-type="bibr" rid="B93">2009</xref>). STS expression is under the control of estrogens in breast cancer (Zaichuk et al., <xref ref-type="bibr" rid="B151">2007</xref>), and it is down-regulated by GnRH agonists (Maitoko and Sasaki, <xref ref-type="bibr" rid="B81">2004</xref>) and danazol (Fechner et al., <xref ref-type="bibr" rid="B34">2007</xref>) in endometriotic tissue. In endometrium, no significant differences in STS expression have been reported at the mRNA level between the proliferative and secretory phases (Colette et al., <xref ref-type="bibr" rid="B21">2013</xref>), while at the protein level, significant down-regulation was seen in the late secretory phase, compared to the menstrual phase (Dassen et al., <xref ref-type="bibr" rid="B23">2007</xref>). STS expression can also be affected by the inflammatory cytokines: interleukin (IL)1α enhanced STS expression and mRNA levels in the SKOV3 epithelial ovarian cancer cell line, but not in the OSE normal ovarian surface epithelium cell line (Ren et al., <xref ref-type="bibr" rid="B114">2015</xref>), and IL1β suppressed STS expression in endometrial stromal cells (Matsuoka et al., <xref ref-type="bibr" rid="B85">2002</xref>). On the other hand, IL6 and tumor necrosis factor (TNF)α increased STS activity in a breast cancer cell line MCF7 not changing the mRNA levels, which suggested posttranslational modifications <italic>via</italic> STS glycosylation (Newman et al., <xref ref-type="bibr" rid="B95">2000</xref>). In contrast, Sung et al. recently reported that in prostate cancer cell line PC-3 both, TNFα and insulin growth factor II regulate STS expression at the transcriptional level (Sung et al., <xref ref-type="bibr" rid="B131">2013</xref>). STS expression is also regulated by micro (mi)RNA, as the overexpression of miR-142-3p significantly reduced STS mRNA levels in the St-T1b human endometrial stromal cell line (Kästingschäfer et al., <xref ref-type="bibr" rid="B68">2015</xref>).</p>
</sec>
<sec id="s2">
<title>Steroid sulfotransferases</title>
<p>The SULTs catalyze the transfer of a sulfuryl group from 3′-phosphoadenosine-5′-phosphosulfate (PAPS) to the target molecule. This conjugation is typically involved in inactivation/detoxification reactions for a variety of substrates, such as xenobiotics, therapeutic drugs, toxic compounds, chemical carcinogens, bile acids, hormones and neurotransmitters, and it is also an important pathway for hormonal regulation (Geese and Raftogianis, <xref ref-type="bibr" rid="B43">2001</xref>). The superfamily of cytosolic human SULTs comprises 13 <italic>SULT</italic> genes and spans four families: SULT1 includes three phenol SULT subfamilies (SULT1A, SULT1B, SULT1C) and an estrogen SULT (SULT1E1); SULT2s catalyze sulfonation of the hydroxyl groups of steroids (SULT2A1, SULT2B1); and there are two orphan SULT families, SULT4 and SULT6 (SULT4A1, SULT6B1) (reviewed in Geese and Raftogianis, <xref ref-type="bibr" rid="B43">2001</xref>; Lindsay et al., <xref ref-type="bibr" rid="B75">2008</xref>). SULT2A1 catalyzes the sulfonation of DHEA, androgens and estrogens, while SULT2B1 catalyzes sulfonation of only DHEA (Lindsay et al., <xref ref-type="bibr" rid="B75">2008</xref>). Although SULTs in general have broad substrate specificity, SULT1E1 (E.C. 2.8.2.4.) has significantly greater affinity for the estrogens than other SULTs, and it inactivates E1 and estradiol (E2) with nM Km values (Falany et al., <xref ref-type="bibr" rid="B30">1995</xref>; Table <xref ref-type="table" rid="T1">1</xref>). SULT2A1 (E.C. 2.8.2.14) and SULT2B1 (E.C. 2.8.2.2) both catalyze sulfation of DHEA, although SULT2A1 shows much higher catalytic efficiency (Lu et al., <xref ref-type="bibr" rid="B76">2008</xref>). The SULTs need PAPS as a coenzyme, and thus SULT expression has to be accompanied by expression of at least one of the two PAPS synthase genes (Mueller et al., <xref ref-type="bibr" rid="B90">2015</xref>).</p>
<p>The <italic>SULT1E1</italic> gene has been localized to chromosome 4 (4q13.2), it has eight exons and a length of 20 kb, and it encodes a protein of 294 amino acids with a molecular mass of 35 kDa (Falany et al., <xref ref-type="bibr" rid="B30">1995</xref>). Recombinant SULT1E1 has been crystalized, and the structure of the binary complex with PAPS (pdb code 1HY3; Pedersen et al., <xref ref-type="bibr" rid="B101">2002</xref>) and several ternary complexes, including a complex with PAP and E2 (pdb code 4JVL; Gosavi et al., <xref ref-type="bibr" rid="B46">2013</xref>), have been resolved. SULT1E1 is a dimer with an α/β motif that consists of five parallel β-strands surrounded by α-helices and a conserved α-helix across this structure (Pedersen et al., <xref ref-type="bibr" rid="B101">2002</xref>) (Figure <xref ref-type="fig" rid="F3">3A</xref>). The structure of the SULT1E1–PAP–E2 complex has revealed that E2 binds to a mostly buried hydrophobic pocket with the sulfuryl acceptor 3′ hydroxyl within H-bonding distance of the proposed catalytic His107, and Lys10. The Phe80 and Phe141 are involved in the positioning of the steroidal substrate and have been suggested to function as a steric gate, thus defining substrate specificity (Gosavi et al., <xref ref-type="bibr" rid="B46">2013</xref>). SULT1E1 has three catalytic amino-acid residues: Lys47, His107, and Ser137 (Negishi et al., <xref ref-type="bibr" rid="B94">2001</xref>). The proposed reaction mechanism is as follows: upon binding of PAPS, Ser137 forms an H-bond with Lys47, thus prevents its interaction with the bridging oxygen in PAPS and its further hydrolysis; His107 attracts a proton from the substrate hydroxyl (i.e., of E2, DHEA), and enables nucleophilic attack at the sulfur atom in PAPS. In the next step, Lys47 interacts with the 5′ phosphate of PAPS, which help in dissociation of the sulfuryl group and in its transfer to the substrate. Finally, the reaction products, PAP and E1-S are released, which completes the catalytic cycle (Gamage et al., <xref ref-type="bibr" rid="B42">2006</xref>; Tibbs et al., <xref ref-type="bibr" rid="B136">2015</xref>) (Figure <xref ref-type="fig" rid="F3">3B</xref>). The crystallization and kinetics data have further suggested that the substrate inhibition that has been observed at high concentrations is a dead-end complex where both PAP and E2 are bound (Gosavi et al., <xref ref-type="bibr" rid="B46">2013</xref>).</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p><bold>Tertiary structure and reaction mechanism of the human SULT1E1 enzyme. (A)</bold> Structure of the human SULT1E1 enzyme in complex with PAP and E2 (pdb 4JVL). <bold>(B)</bold> Reaction mechanism and the roles of catalytical amino-acid residues His107, Lys47, and Ser137. The scheme was adopted from Thomas and Potter (<xref ref-type="bibr" rid="B134">2013</xref>).</p>
</caption>
<graphic xlink:href="fphar-07-00030-g0003"></graphic>
</fig>
<p>For the <italic>SULT1E1</italic> gene, in addition to the primary transcript, there are two variant transcripts (i.e., variants X1, X2) that encode proteins of 294 amino acids and 181 amino acids. Currently more than 150 cSNPs are included in the SNP database for <italic>SULT1E1</italic>, but none show MAF &gt;0.01 (Table <xref ref-type="table" rid="T2">2</xref>). Functional analysis has revealed decreased SULT1E1 activities for two nonsynonymous coding SNPs: Asp22Tyr and Ala32Val (Adjei et al., <xref ref-type="bibr" rid="B3">2003</xref>). These cSNPs were found in African-American (Asp22Tyr) and Caucasian (Ala32Val) populations (Adjei et al., <xref ref-type="bibr" rid="B3">2003</xref>). Additionally, the SNP rs6259 in the promoter region of <italic>SULT1E1</italic> has been associated with increased risk of endometrial cancer (Rebbeck et al., <xref ref-type="bibr" rid="B111">2006</xref>; Hirata et al., <xref ref-type="bibr" rid="B57">2008</xref>), and SNPs <sup>*</sup>959 G&gt;A and IVS4-1653 T&gt;C with increased recurrence of endometrial cancer (Choi et al., <xref ref-type="bibr" rid="B18">2005</xref>).</p>
<p><italic>SULT1E1</italic> is expressed in liver, secretory endometrium, fetal liver, lung, and kidney (Coughtrie, <xref ref-type="bibr" rid="B22">2002</xref>). Expression of <italic>SULT1E1</italic> is regulated by steroid hormones. In the normal endometrium, the highest expression of <italic>SULT1E1</italic> was found for the secretory phase, which is consistent with regulation by progesterone (Falany and Falany, <xref ref-type="bibr" rid="B31">1996</xref>; Rubin et al., <xref ref-type="bibr" rid="B118">1999</xref>; Dassen et al., <xref ref-type="bibr" rid="B23">2007</xref>), although Colette et al. recently reported that <italic>SULT1E1</italic> expression is unchanged in the proliferative and secretory phases (Colette et al., <xref ref-type="bibr" rid="B21">2013</xref>). In endometrial cancer cell line Ishikawa <italic>SULT1E1</italic> is induced by steroid drug tibolone via progesterone receptor (Falany and Falany, <xref ref-type="bibr" rid="B32">2006</xref>), while in liver it is repressed by xenobiotic activators of the pregnane X receptor and aryl hydrocarbon receptor peroxisome proliferator, and activated via peroxisome proliferator activated receptor α and the liver X receptor (Duanmu et al., <xref ref-type="bibr" rid="B26">2007</xref>). Furthermore, studies have implied that <italic>SULT1E1</italic> is also epigenetically regulated, as its expression is induced by the histone deacetylase inhibitor trichostatin A in MCF10A cells (Fu et al., <xref ref-type="bibr" rid="B41">2010</xref>). SULT1E1 activity is also affected by ubiquitous pollutants, such as the polychlorinated biphenyls, which act as potent inhibitors with Ki values in the pM range, and thus they can exert their endocrine disrupting effects without binding to steroid hormone receptors (Kester et al., <xref ref-type="bibr" rid="B65">2000</xref>).</p>
<p>The <italic>SULT2A1</italic> gene has been localized to chromosome 19 (19q13.3). It has six exons and a total length of 16 kb (Freimuth et al., <xref ref-type="bibr" rid="B40">2004</xref>), with only one transcript known, which encodes a protein with 285 amino acids and a molecular mass of 34 kDa (Table <xref ref-type="table" rid="T2">2</xref>). Several crystal structures of SULT2A1 binary complexes have been resolved (Tibbs et al., <xref ref-type="bibr" rid="B136">2015</xref>), including complexes with DHEA (pdb code 1J99; Rehse et al., <xref ref-type="bibr" rid="B113">2002</xref>) and PAPS (pdb code 4IFB). The complete kinetic mechanism of SULT2A1 has been defined, which revealed that the binding of DHEA and PAPS is random, while the rate-limiting step is nucleotide release. Here, the potent substrate inhibition with a Ki of 6.1 μM for DHEA can be explained by trapping PAP in a dead-end complex, which impedes the release of the nucleotide coenzyme (Wang et al., <xref ref-type="bibr" rid="B144">2014</xref>).</p>
<p><italic>SULT2A1</italic> is expressed in liver, adrenal gland, fetal adrenal, and fetal liver (Luu-The et al., <xref ref-type="bibr" rid="B78">1995</xref>; Coughtrie, <xref ref-type="bibr" rid="B22">2002</xref>). SULT2A1 has broad substrate specificity, as it can catalyze sulfonation of many hydroxysteroids, including DHEA, epiandrosterone, androsterone, testosterone, E2, cholesterol, various bile acids, pregnenolone, 17-ethinyl-E2 and cortisol (Lindsay et al., <xref ref-type="bibr" rid="B75">2008</xref>). More than 160 cSNPs have been reported for <italic>SULT2A1</italic> (Table <xref ref-type="table" rid="T2">2</xref>). Functional analysis has revealed that the nonsynonymous SNPs Met57Thr, Glu186Val, Ala63Pro, and Lys227Glu result in decreased SULT2A1 activity when expressed in COS-1 cells (Nagata and Yamazoe, <xref ref-type="bibr" rid="B91">2000</xref>). Interestingly, the <italic>SULT2A1</italic> SNPs Ala63Pro, Lys227Glu and Ala261Thr have only been found in African-American populations, and these might explain the reported interethnic differences in SULT2A1 activity (Thomae et al., <xref ref-type="bibr" rid="B133">2002</xref>; Hildebrandt et al., <xref ref-type="bibr" rid="B56">2007</xref>). The <italic>SULT2A1</italic> SNP Ala261Thr has an allele frequency of 13% in African-American populations (reported MAF, 0.0407) and is located within the dimerization motif, where it prevents formation of SULT2A1 dimers. Surprisingly Ala261Thr still has 93% of the wild-type enzyme activity. Also Ala63Pro is quite common, with an allele frequency of 5% in African-American populations, and a reported MAF of 0.024 (Table <xref ref-type="table" rid="T2">2</xref>).</p>
<p>The expression of <italic>SULT2A1</italic> is regulated at the transcriptional level by the constitutive androstane receptor and pregnane X receptor (Echchgadda et al., <xref ref-type="bibr" rid="B27">2007</xref>). As recently shown in human hepatocytes and the HepG2 cell line, the <italic>SULT2A1</italic> gene is induced by E2 activation of estrogen receptor (ER)α via classical, direct binding to the estrogen response element, and via nonclassical, AP-1–mediated mechanisms (Li et al., <xref ref-type="bibr" rid="B74">2014</xref>). <italic>SULT2A1</italic> appears to be regulated also at the epigenetic level, as shown by induction of <italic>SULT2A1</italic> expression after treatment of MCF7 cells with a histone deacetylase inhibitor (Fu et al., <xref ref-type="bibr" rid="B41">2010</xref>). In the adrenal gland, the expression of <italic>SULT2A1</italic> depends on two transcription factors: steroidogenic factor 1 and GATA-6 (Saner et al., <xref ref-type="bibr" rid="B121">2005</xref>).</p>
<p>The SULT2B1 isoforms SULT2B1a and SULT2B1b are products of alternative transcriptional initiation and mRNA splicing of the same gene, and are expressed in different tissues. SULT1B1a is expressed in colon, ovary, and fetal brain, and SULT2B1b in liver, colon, small intestine, placenta, ovary, uterus, and prostate (Geese and Raftogianis, <xref ref-type="bibr" rid="B43">2001</xref>). SULT1B1a and SULT1B1b, which has an additional 23 N-terminal amino-acid residues, have been cloned and expressed in prokaryotic and eukaryotic systems, and purified and characterized (Geese and Raftogianis, <xref ref-type="bibr" rid="B43">2001</xref>; Meloche and Falany, <xref ref-type="bibr" rid="B86">2001</xref>). These enzymes catalyze sulfonation of 3β-hydroxysteroids, pregnenolone, 17α-hydroxypregnenolone and DHEA (Geese and Raftogianis, <xref ref-type="bibr" rid="B43">2001</xref>). The structures of both SULT2B1a and SULT2B1b in binary complexes with PAP (pdb codes 1Q1Q, 1Q1Z, respectively Lee et al., <xref ref-type="bibr" rid="B73">2003</xref>) have been resolved, as have two ternary complexes of SULT1Bb with PAP and pregnenolone (pdb code 1Q2O; Lee et al., <xref ref-type="bibr" rid="B73">2003</xref>), and with PAP and DHEA (pdb code 1Q22, Lee et al., <xref ref-type="bibr" rid="B73">2003</xref>; Tibbs et al., <xref ref-type="bibr" rid="B136">2015</xref>).</p>
<p>The <italic>SULT2B1</italic> gene has been localized to chromosome 19 (19g13.3), and it comprises six exons with a total length of 48 kb (Geese and Raftogianis, <xref ref-type="bibr" rid="B43">2001</xref>; Meloche and Falany, <xref ref-type="bibr" rid="B86">2001</xref>; Freimuth et al., <xref ref-type="bibr" rid="B40">2004</xref>). Three transcripts have been identified (variants 1, 2, X1) that encode proteins of 350, 365, and 221 amino acids (Table <xref ref-type="table" rid="T2">2</xref>). Although more than 200 coding SNPs for <italic>SULT2B1</italic> are currently included in the SNP database, there is only one nonsynonymous SNP: Arg33Gln, with MAF &gt;0.01 (Table <xref ref-type="table" rid="T2">2</xref>). So far, only a few of these SNPs have been studied in more detail. Recently, Lévesque et al. (<xref ref-type="bibr" rid="B80">2014</xref>) reported that <italic>SULT2B1</italic> SNPs rs12460535, rs2665582, and rs10426628 are significantly associated with prostate cancer progression and hormone levels.</p>
<p>The SULT enzymes are known to show profound substrate inhibition, and SULT2B1 is not an exception. DHEA inhibits SULT2B1a and SULT2B1b with Ki values of 48 μM and 22 μM, respectively (Geese and Raftogianis, <xref ref-type="bibr" rid="B43">2001</xref>). Not much is known about the regulation of <italic>SULT2B1</italic>. In normal endometrium, higher SULT2B1b mRNA levels have been seen in the mid-luteal phase, in agreement with progesterone regulation (Koizumi et al., <xref ref-type="bibr" rid="B69">2010</xref>). In human endometrial stromal cells, the levels of SULT2B1b transcript were increased by cAMP or progesterone, while they were increased by cAMP or relaxin in endometrial epithelial cells, stimulating protein kinase A pathway (Koizumi et al., <xref ref-type="bibr" rid="B69">2010</xref>). In prostate cancer cells, expression of SULT1B1b was shown to be regulated by vitamin D via heterodimer of vitamin D receptor and retinoid X receptor α (Seo et al., <xref ref-type="bibr" rid="B122">2013</xref>).</p>
</sec>
<sec id="s3">
<title>Local production of estrogens from DHEA-S and E1-S</title>
<p>STS and SULTs have pivotal roles in estrogen synthesis in peripheral tissues, and thus also in pre-receptor regulation of steroid hormone action. In premenopausal women, estrogens can be synthesized in the ovaries and in peripheral tissues (Labrie, <xref ref-type="bibr" rid="B70">1991</xref>; Simpson, <xref ref-type="bibr" rid="B123">2003</xref>). After menopause, when the ovaries cease to act, estrogens are formed only in the peripheral sites, which mainly include adipose tissue, but also bone, vascular endothelium, aortic smooth muscle cells, and brain (Simpson, <xref ref-type="bibr" rid="B123">2003</xref>). Locally, estrogens can be formed from the inactive precursors of adrenal origin, DHEA-S, DHEA, and androstenedione, and of ovarian origin, DHEA and androstenedione, or from circulating E1-S (Figure <xref ref-type="fig" rid="F1">1</xref>). These steroid precursors are at relatively high concentrations in the blood of premenopausal and postmenopausal women, with DHEA-S at 3.4 ± 1.7 μM and 1.6 ± 1.0 μM, respectively (Labrie et al., <xref ref-type="bibr" rid="B71">2006</xref>). DHEA and androstenedione are at 15.5 ± 7.6 nM and 3.4 ± 1.2 nM respectively, in premenopausal women, and 6.8 ± 4.1 nM and 1.4 ± 0.6 nM, respectively, in postmenopausal women (Labrie et al., <xref ref-type="bibr" rid="B71">2006</xref>). Estrogens can thus be produced via the so-called aromatase pathway, from androstenedione and testosterone, by the actions of aromatase and 17-ketosteroid reductases (i.e., 17β-hydroxysteroid dehydrogenases; HSD17B), mainly HSD17B1. Estrogens can also be formed from DHEA-S by the actions of STS, 3β-hydroxysteroid dehydrogenases-Δ<sup>4</sup>-isomerase (HSD3B1, HSD3B2), aromatase (CYP19A1) and HSD17B or aldo-keto reductase 1C3 (AKR1C3) and CYP19A1, and from E1-S by the actions of STS and HSD17B (Rižner, <xref ref-type="bibr" rid="B116">2013</xref>; Figure <xref ref-type="fig" rid="F1">1</xref>). The formation of E2 from E1-S is known as the STS pathway. E1-S is the most important estrogen in the peripheral blood, at 1.8 ± 1.1 nM and 0.6 ± 0.03 nM in premenopausal and postmenopausal women, respectively (Caron et al., <xref ref-type="bibr" rid="B16">2009</xref>; Labrie et al., <xref ref-type="bibr" rid="B72">2009</xref>). Studies in breast and endometrial cancers have shown that the STS pathway prevails over the aromatase pathway (Pasqualini et al., <xref ref-type="bibr" rid="B98">1996</xref>; Chetrite et al., <xref ref-type="bibr" rid="B17">2000</xref>; Purohit et al., <xref ref-type="bibr" rid="B108">2011</xref>; Rižner, <xref ref-type="bibr" rid="B116">2013</xref>). Higher E1-S, E1, and E2 plasma concentrations were observed for patients with breast cancer and endometrial cancer, compared to control women (Lépine et al., <xref ref-type="bibr" rid="B79">2010</xref>; Tworoger et al., <xref ref-type="bibr" rid="B138">2014</xref>) and high E1-S and E2 have been measured in breast cancer tissue (Chetrite et al., <xref ref-type="bibr" rid="B17">2000</xref>), with high E2 and a high E2 to E1-S ratio reported in endometrial cancer tissue (Naitoh et al., <xref ref-type="bibr" rid="B92">1989</xref>; Berstein et al., <xref ref-type="bibr" rid="B8">2003</xref>). Most importantly, the levels of estrogens in breast and endometrial cancer tissue are 2- to 40-fold higher compared to plasma concentrations (Pasqualini et al., <xref ref-type="bibr" rid="B98">1996</xref>; Berstein et al., <xref ref-type="bibr" rid="B8">2003</xref>), further supporting intracrine formation and actions of estrogens.</p>
<p>DHEA-S and E1-S can thus serve as precursors for E2 formation after their translocation into cells via the transporter proteins of the organic anion-transporting polypeptide and organic anion-transporter families (Mueller et al., <xref ref-type="bibr" rid="B90">2015</xref>). STS can then hydrolyze DHEA-S and E1-S to DHEA and E1, respectively, while the SULTs can catalyze the reverse reactions. SULT1E1 inactivates E1 and E2 to form the corresponding sulfates, and SULT2A1 and SULT2B1 conjugate DHEA (Raftogianis et al., <xref ref-type="bibr" rid="B109">2000</xref>; Meloche and Falany, <xref ref-type="bibr" rid="B86">2001</xref>; Gamage et al., <xref ref-type="bibr" rid="B42">2006</xref>; Pasqualini, <xref ref-type="bibr" rid="B97">2009</xref>). The sulfated steroids can then be excreeted from the cells via the ABC transporters (Mueller et al., <xref ref-type="bibr" rid="B90">2015</xref>). The resulting increased uptake together with the decreased excretion of DHEA-S and E1-S, and the disturbed delicate balance between the STS and SULT enzymes, might thus lead to increased levels of estrogens, which are associated with hormone-dependent diseases, including several gynecological diseases.</p>
</sec>
<sec id="s4">
<title>Sulfatase and sulfotransferases in gynecological diseases</title>
<p>Benign gynecological diseases such as endometriosis, adenomyosis, and uterine fibroids, and gynecological cancers such as endometrial cancer and ovarian cancer, affect a large proportion of women. The benign diseases are associated with infertility, and they can significantly decrease quality of life, while gynecological cancers comprise more than 10% of cancer-related deaths in women worldwide (Ferlay et al., <xref ref-type="bibr" rid="B35">2013</xref>). These diseases are mainly hormone-dependent and thus rely on the local formation of active steroid hormones.</p>
<sec>
<title>Sulfatase and sulfotransferase in endometriosis</title>
<p>Endometriosis is a frequent benign gynecological disease that is characterized by the presence of endometrial tissue outside the uterine cavity. In the general population of women of reproductive age, the predicted prevalence of endometriosis is 6–10%, but the frequency increases to 30–50% in women with pain, infertility, or both (Guo and Wang, <xref ref-type="bibr" rid="B49">2006</xref>; Rogers et al., <xref ref-type="bibr" rid="B117">2013</xref>). Ectopic endometrial tissue can be found in different parts of the peritoneal cavity, where these locations define three different entities with different etiologies and pathogenesis: ovarian, peritoneal, and deep infiltrating endometriosis (Brosens and Benagiano, <xref ref-type="bibr" rid="B12">2011</xref>). Endometriosis is an estrogen-dependent disease where endometriotic tissue proliferates in response to systemic estrogens and estrogens formed locally through the aromatase and the sulphatase pathways (Huhtinen et al., <xref ref-type="bibr" rid="B60">2009</xref>; Rižner, <xref ref-type="bibr" rid="B115">2009</xref>). However, the STS pathway appears to outperform the aromatase pathway, as the aromatase activity in endometriotic tissue is negligible when compared to STS activity (Purohit et al., <xref ref-type="bibr" rid="B106">2008</xref>; Delvoux et al., <xref ref-type="bibr" rid="B25">2009</xref>).</p>
<p>Data on expression of <italic>STS</italic> in endometriosis have remained relatively contradictory (Table <xref ref-type="table" rid="T3">3</xref>). Although metabolism studies have revealed significantly lower STS activity in ectopic than eutopic endometrium of patients with ovarian endometriosis (Carlström et al., <xref ref-type="bibr" rid="B15">1988</xref>), significantly higher levels of <italic>STS</italic> mRNA were seen for samples of ovarian endometriosis compared to eutopic endometrium from control patients (Smuc et al., <xref ref-type="bibr" rid="B125">2007</xref>, <xref ref-type="bibr" rid="B124">2009</xref>). Also, in peritoneal endometriosis, STS activity was lower in ectopic than matched eutopic endometrium, but it still correlated with severity of disease and was higher in moderate/severe disease vs. minimal/mild disease (Purohit et al., <xref ref-type="bibr" rid="B106">2008</xref>). At the mRNA level, Collete et al. observed no significant differences between peritoneal endometriosis (ectopic) and control (eutopic) endometrial tissue but found higher levels in deep infiltrating endometriosis compared to ovarian endometriosis (Colette et al., <xref ref-type="bibr" rid="B21">2013</xref>). Deep infiltrating endometriosis, Dassen et al. found no differences in <italic>STS</italic> expression between ectopic and eutopic endometrium of patients and the normal endometrium of the control group, while they found significantly lower protein levels of STS in epithelial cells of eutopic endometrium compared to normal endometrium (Dassen et al., <xref ref-type="bibr" rid="B23">2007</xref>). Delvoux et al. reported unchanged STS activity in samples from all three types of endometriosis (Delvoux et al., <xref ref-type="bibr" rid="B25">2009</xref>). However, Purohit et al. reported that STS activity in peritoneal ectopic implants and matched eutopic endometrium was higher than aromatase activity, which thus suggested that the STS pathway is important in estrogen formation and that STS inhibitors might be useful for treatment of endometriosis (Purohit et al., <xref ref-type="bibr" rid="B106">2008</xref>; Delvoux et al., <xref ref-type="bibr" rid="B25">2009</xref>).</p>
<table-wrap id="T3" position="float">
<label>Table 3</label>
<caption>
<p><bold>Expression of STS and SULTs in endometriosis</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Level</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Regulation</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>STS</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">mRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> OE/control endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Smuc et al., <xref ref-type="bibr" rid="B125">2007</xref>, <xref ref-type="bibr" rid="B124">2009</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">≈ DIE/eutopic/normal endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dassen et al., <xref ref-type="bibr" rid="B23">2007</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1" style="border-bottom: thin solid #000000;"></td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> DIE/OE; ≈ PE/OE/eutopic endometrium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Colette et al., <xref ref-type="bibr" rid="B21">2013</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Protein</td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0002.jpg"></inline-graphic> eutopic/normal endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dassen et al., <xref ref-type="bibr" rid="B23">2007</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1" style="border-bottom: thin solid #000000;"></td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">≈ ectopic/eutopic endometrium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Colette et al., <xref ref-type="bibr" rid="B21">2013</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Activity (E1-S)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0002.jpg"></inline-graphic> ectopic/eutopic</td>
<td align="left" colspan="1" rowspan="1" valign="top">Carlström et al., <xref ref-type="bibr" rid="B15">1988</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0002.jpg"></inline-graphic> PE/eutopic endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Purohit et al., <xref ref-type="bibr" rid="B106">2008</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> moderate/severe/minimal/mild</td>
<td align="left" colspan="1" rowspan="1" valign="top">Purohit et al., <xref ref-type="bibr" rid="B106">2008</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">≈ ectopic/eutopic/control endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Delvoux et al., <xref ref-type="bibr" rid="B25">2009</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SULT1E1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">mRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">≈ OE/control endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Smuc et al., <xref ref-type="bibr" rid="B125">2007</xref>, <xref ref-type="bibr" rid="B124">2009</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> DIE/normal endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dassen et al., <xref ref-type="bibr" rid="B23">2007</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">≈ DIE, OE, PE/eutopic endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Colette et al., <xref ref-type="bibr" rid="B21">2013</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0002.jpg"></inline-graphic> OE/normal endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hevir et al., <xref ref-type="bibr" rid="B53">2013</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1" style="border-bottom: thin solid #000000;"></td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0002.jpg"></inline-graphic> OE/eutopic endometrium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Borghese et al., <xref ref-type="bibr" rid="B10">2008</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Protein</td>
<td align="left" colspan="1" rowspan="1" valign="top">≈ OE, PE/eutopic/control endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hudelist et al., <xref ref-type="bibr" rid="B59">2007</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SULT2B1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">mRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0002.jpg"></inline-graphic> OE/normal endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hevir et al., <xref ref-type="bibr" rid="B53">2013</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>OE, ovarian endometriosis; PE, peritoneal endometriosis; DIE, deep infiltrating endometriosis</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>In addition to STS, SULTs should also be taken into account when evaluating the importance of the STS pathway, as both of these enzymes affect the subtle balance between estrogen activation (E1-S hydrolysis) and estrogen inactivation (E1, E2 sulfation). Expression of <italic>SULT</italic>s has been investigated in several studies (Table <xref ref-type="table" rid="T3">3</xref>). In ectopic tissue of patients with ovarian, peritoneal, and deep infiltrating endometriosis, no significant differences in the expression of <italic>SULT1E1</italic> was seen at the mRNA level (Smuc et al., <xref ref-type="bibr" rid="B125">2007</xref>, <xref ref-type="bibr" rid="B124">2009</xref>; Colette et al., <xref ref-type="bibr" rid="B21">2013</xref>), while there were significantly higher mRNA levels in ectopic endometrium of deep infiltrating endometriosis, when compared to the normal endometrium (Dassen et al., <xref ref-type="bibr" rid="B23">2007</xref>). On the other hand, Borghese et al. and Hevir et al. found decreased mRNA levels in ovarian endometriosis vs. control eutopic endometrium from patients (Borghese et al., <xref ref-type="bibr" rid="B10">2008</xref>) and control normal endometrium (Hevir et al., <xref ref-type="bibr" rid="B53">2013</xref>), respectively. At the protein level, Hudelist et al. saw no differences between ovarian and peritoneal endometriotic lesions and eutopic endometrium (Hudelist et al., <xref ref-type="bibr" rid="B59">2007</xref>). The expression of <italic>SULT2A1</italic> has not been studied in this context, but the expression of <italic>SULT2B1</italic> at the mRNA level was decreased in ovarian endometriosis compared to normal endometrium (Hevir et al., <xref ref-type="bibr" rid="B53">2013</xref>); which implies that DHEA-S may serve as a precursor steroid in this ectopic tissue.</p>
<p>Data on the expression of the <italic>STS</italic> and <italic>SULT</italic> genes at the mRNA, protein and enzymatic activity levels in endometriosis tissue vs. control tissue are contradictory and do not fully support the importance of the sulfatase pathway. As different types of endometriosis show variations in the expression of these genes, it seems that the sulfatase may have roles primarily in ovarian endometriosis. Furthermore, the majority of studies have compared endometriotic tissue with eutopic endometrium of the same patient, which might not be the optimal study design. Nowadays, it is generally accepted that eutopic endometrium of endometriosis patients has already undergone pathological transformations, and that the gene expression profile in this tissue can be used as a biomarker of endometriosis (Burney et al., <xref ref-type="bibr" rid="B14">2007</xref>).</p>
</sec>
<sec>
<title>Sulfatase and sulfotransferase in adenomyosis</title>
<p>Adenomyosis is a benign gynecological disease that is defined as the presence of endometrial glands and stroma within the muscular layer of the uterus (i.e., myometrial tissue) (Kitawaki, <xref ref-type="bibr" rid="B66">2006</xref>; Graziano et al., <xref ref-type="bibr" rid="B47">2015</xref>). The symptoms that appear in two-thirds of patients with adenomyosis are dysmenorrhea, metrorrhagia, chronic pelvic pain, dyspareunia, and infertility. The prevalence of adenomyosis varies among studies, with 5–70% reported (Graziano et al., <xref ref-type="bibr" rid="B47">2015</xref>). Adenomyosis mainly affects women in late reproductive age and regresses after menopause (Kitawaki, <xref ref-type="bibr" rid="B66">2006</xref>). It is thus considered an estrogen-dependent disease, and is often associated with other estrogen-dependent pathologies, such as endometriosis, leiomyoma, and hyperplasia, and also with endometrial cancer (Kitawaki, <xref ref-type="bibr" rid="B66">2006</xref>). Furthermore, expression of aromatase in adenomyotic tissue is also implicative of estrogen dependency (Kitawaki et al., <xref ref-type="bibr" rid="B67">1997</xref>). However, the STS pathway for the local formation of estrogens has been studied by only two groups (Table <xref ref-type="table" rid="T4">4</xref>). Ezaki et al. observed increased STS protein levels in adenomyotic tissue vs. the basilar layer of normal endometrium (Ezaki et al., <xref ref-type="bibr" rid="B29">2001</xref>), and Yamamoto et al. reported increased E1-S STS activity in adenomyosis, which was reduced by danazol treatment (Yamamoto et al., <xref ref-type="bibr" rid="B148">1993</xref>). Although the involvement of estrogens in the pathophysiology of adenomyosis has not been sufficiently studied, and thus further investigations into estrogen biosynthesis and actions in this gynecological disease are warranted, the published data indicates importance of the sulfatase pathway.</p>
<table-wrap id="T4" position="float">
<label>Table 4</label>
<caption>
<p><bold>Expression of STS in adenomyosis</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Level</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Regulation</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>STS</italic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Protein</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> adenomyotic tissue/basilar layer of endometrium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Ezaki et al., <xref ref-type="bibr" rid="B29">2001</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Activity (E1-S)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> STS <inline-graphic xlink:href="fphar-07-00030-i0002.jpg"></inline-graphic> danazol treatment</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yamamoto et al., <xref ref-type="bibr" rid="B148">1993</xref></td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Sulfatase and sulfotransferase in uterine fibroids</title>
<p>Uterine fibroids (leiomyomas; <italic>myoma uteri</italic> or <italic>uterus myomatosus</italic>) are benign tumors of the myometrium that occur in up to 70% of women of reproductive age (Bulun, <xref ref-type="bibr" rid="B13">2013</xref>). However, the clinically significant symptoms that include heavy menstrual bleeding, anemia, difficulties with conceiving, and increased risk of miscarriage, are seen in one-third of the affected population (Bulun, <xref ref-type="bibr" rid="B13">2013</xref>). Uterine fibroids appear after menarche and decline after menopause, which implicates the estrogens as the primary factor that drives their growth. Additionally, studies showed that estrogens are necessary, but not sufficient for proliferation and progesterone also has an important role in growth of leiomyomas. Estrogens act via estrogen receptor α and thus stimulate expression of progesterone receptors and further pro-proliferative action of progesterone (Moravek et al., <xref ref-type="bibr" rid="B88">2015</xref>).</p>
<p>Based on PubMed searches, there has been only one report on the STS pathway in myoma tissue (Table <xref ref-type="table" rid="T5">5</xref>). The Okada group examined E1-S hydrolysis and E1 sulfation in myoma tissue vs. myometrium, and they showed decreased STS and increased SULT activities (Yamamoto et al., <xref ref-type="bibr" rid="B149">1990</xref>, <xref ref-type="bibr" rid="B148">1993</xref>), thus suggesting that more estrogens can be formed in the surrounding myometrium than in the myoma tissue. In this way, estrogens might still act in a paracrine manner to provide myoma tissue with the mitogenic E2. As other studies showed that aromatase is upregulated, the local estrogen formation via the aromatase pathway probably has more important role. Furthermore, the effects of gonadotropin-releasing hormone analogs on the levels of estrogens and STS activity have also been examined in myoma where lower levels of estrogens (Pasqualini et al., <xref ref-type="bibr" rid="B99">1990</xref>; van de Ven et al., <xref ref-type="bibr" rid="B142">2002</xref>) and no significant effects on STS activity (van de Ven et al., <xref ref-type="bibr" rid="B142">2002</xref>) were seen. So far the roles of the sulfatase pathway in uterine fibroids have not been thoroughly examined, which calls for further studies.</p>
<table-wrap id="T5" position="float">
<label>Table 5</label>
<caption>
<p><bold>Expression of STS and SULT in myoma uteri</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Level</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Regulation</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>STS</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activity (E1-S)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0002.jpg"></inline-graphic> myoma vs. myometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yamamoto et al., <xref ref-type="bibr" rid="B149">1990</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SULT1E1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Activity (E1)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> myoma vs. myometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Yamamoto et al., <xref ref-type="bibr" rid="B149">1990</xref></td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Sulfatase and sulfotransferase in endometrial cancer</title>
<p>Endometrial cancer is the most common gynecological malignancy in the developed world. Worldwide, 319,605 new cases of endometrial cancer and 76,160 deaths were estimated for 2012 (Ferlay et al., <xref ref-type="bibr" rid="B35">2013</xref>). Based on histopathology, the majority of endometrial cancers can be divided into two groups: type 1 with an endometrioid histology, which comprises 70–80% of all cases (Yeramian et al., <xref ref-type="bibr" rid="B150">2013</xref>); and type 2 with serous papillary or clear-cell histology, which comprise 20% of all cases. Type 1 endometrial cancer is considered to be estrogen dependent, and type 2 not to be associated with hyper-estrogenic factors (Amant et al., <xref ref-type="bibr" rid="B5">2005</xref>; Ryan et al., <xref ref-type="bibr" rid="B119">2005</xref>). Development of type 1 endometrial cancer is usually explained by the unopposed estrogen hypothesis, which proposes that exposure to estrogens (of either endogenous or exogenous origins) that is not opposed by progesterone or synthetic progestins increases the mitotic activity of endometrial cells and the number of DNA replication errors. This can lead to somatic mutations that can result in malignant phenotypes (Henderson and Feigelson, <xref ref-type="bibr" rid="B50">2000</xref>; Akhmedkhanov et al., <xref ref-type="bibr" rid="B4">2001</xref>; Inoue, <xref ref-type="bibr" rid="B61">2001</xref>; Sonoda and Barakat, <xref ref-type="bibr" rid="B127">2006</xref>). In line with intracrine estrogen action the formation of estrogens has been detected in proliferative and secretory endometrium and in endometrial cancer tissues (Tseng et al., <xref ref-type="bibr" rid="B137">1982</xref>). Additionally, increased E2 concentrations have been reported in cancerous endometrium of premenopausal and postmenopausal women with type 1 and type 2 endometrial cancer (Bonney et al., <xref ref-type="bibr" rid="B9">1986</xref>; Berstein et al., <xref ref-type="bibr" rid="B8">2003</xref>), and higher E1-S plasma concentrations were observed for endometrial cancer patients, compared to control healthy postmenopausal women (Jasonni et al., <xref ref-type="bibr" rid="B63">1984</xref>).</p>
<p>Expression of STS and its activity in endometrial cancer have been evaluated in nine studies (Table <xref ref-type="table" rid="T6">6</xref>). No significant differences in <italic>STS</italic> expression (Smuc and Rizner, <xref ref-type="bibr" rid="B126">2009</xref>) and increased mRNA levels of <italic>STS</italic> (Lépine et al., <xref ref-type="bibr" rid="B79">2010</xref>) have been reported in endometrial cancer vs. adjacent control tissue. At the cellular level, STS immunoreactivity in endometrial cancer tissue was higher compared to normal endometrium (Utsunomiya et al., <xref ref-type="bibr" rid="B141">2004</xref>), which suggests increased availability of the biologically active estrogens. In line with this, immunohistochemical data and early metabolism studies have shown significantly higher E1-S STS activity in endometrial cancer tissue, compared to control endometrium (Adessi et al., <xref ref-type="bibr" rid="B2">1984</xref>; Prost et al., <xref ref-type="bibr" rid="B105">1984</xref>; Naitoh et al., <xref ref-type="bibr" rid="B92">1989</xref>; Urabe et al., <xref ref-type="bibr" rid="B140">1989</xref>). However, more recently, Tanaka et al. reported lower E1-S STS activity in cancerous tissue, compared to normal endometrium (Tanaka et al., <xref ref-type="bibr" rid="B132">2003</xref>). This discordance might be explained by the different control groups or menopausal stages of the cases and controls. Increased DHEA-S STS activity has also been observed in endometrial cancer, compared to normal endometrium (Abulafia et al., <xref ref-type="bibr" rid="B1">2009</xref>).</p>
<table-wrap id="T6" position="float">
<label>Table 6</label>
<caption>
<p><bold>Expression of STS and SULTs in endometrial cancer</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Level</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Regulation</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>STS</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">mRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">≈ Cancer/adjacent tissue; EC type 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Smuc and Rizner, <xref ref-type="bibr" rid="B126">2009</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1" style="border-bottom: thin solid #000000;"></td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> Cancer/adjacent tissue; EC type 1 (74%) and type 2 (26%)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Lépine et al., <xref ref-type="bibr" rid="B79">2010</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Protein</td>
<td align="left" colspan="1" rowspan="1" valign="top">86% EC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Utsunomiya et al., <xref ref-type="bibr" rid="B141">2004</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1" style="border-bottom: thin solid #000000;"></td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">82% Cancer weak to moderate/normal endometrium weak (glandular cells)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Human Protein Atlas</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Activity (E1-S)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> EC/normal endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Adessi et al., <xref ref-type="bibr" rid="B2">1984</xref>; Prost et al., <xref ref-type="bibr" rid="B105">1984</xref>; Naitoh et al., <xref ref-type="bibr" rid="B92">1989</xref>; Urabe et al., <xref ref-type="bibr" rid="B140">1989</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1" style="border-bottom: thin solid #000000;"></td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0002.jpg"></inline-graphic> EC/normal endometrium</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Tanaka et al., <xref ref-type="bibr" rid="B132">2003</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">DHEA-S</td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> EC/normal endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Abulafia et al., <xref ref-type="bibr" rid="B1">2009</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SULT1E1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">mRNA</td>
<td align="left" colspan="1" rowspan="1" valign="top">≈ Cancer/adjacent tissue; EC type 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hevir et al., <xref ref-type="bibr" rid="B54">2011</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1" style="border-bottom: thin solid #000000;"></td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Borderline <inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> Cancer/adjacent tissue; EC type 1 (74%) and type 2 (26%)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Lépine et al., <xref ref-type="bibr" rid="B79">2010</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Protein</td>
<td align="left" colspan="1" rowspan="1" valign="top">22% EC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Utsunomiya et al., <xref ref-type="bibr" rid="B141">2004</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> EC/adjacent endometrium</td>
<td align="left" colspan="1" rowspan="1" valign="top">Xu et al., <xref ref-type="bibr" rid="B147">2012</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Not detected in cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Human Protein Atlas</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SULT2B1</italic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">mRNA</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> Cancer/adjacent tissue; EC type 1</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Hevir et al., <xref ref-type="bibr" rid="B54">2011</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Protein</td>
<td align="left" colspan="1" rowspan="1" valign="top">Moderate staining in cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Human Protein Atlas</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>EC, endometrial cancer</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>In cancerous and adjacent control endometrium, <italic>SULT1E1</italic> mRNA levels were reported to be unchanged or borderline significantly up-regulated (Lépine et al., <xref ref-type="bibr" rid="B79">2010</xref>; Hevir et al., <xref ref-type="bibr" rid="B54">2011</xref>; Table <xref ref-type="table" rid="T6">6</xref>). The study by Lépine et al. (<xref ref-type="bibr" rid="B79">2010</xref>) included 26% type 2 endometrial cancer patients, which might explain these differences observed. At the cellular level, SULT1E1 immunoreactivity was diminished (Utsunomiya et al., <xref ref-type="bibr" rid="B141">2004</xref>) or was not detected (<ext-link ext-link-type="uri" xlink:href="http://www.proteinatlas.org">www.proteinatlas.org</ext-link>; Uhlén et al., <xref ref-type="bibr" rid="B139">2015</xref>) in endometrial cancer, compared to normal endometrium, while in other studies, increased SULT1E1 staining has been observed in cancerous endometrium, compared to adjacent control endometrium (Xu et al., <xref ref-type="bibr" rid="B147">2012</xref>). These differences can be explained by different antibodies used. As <italic>SULT2A1</italic> is not expressed in either endometrial cancer or adjacent control endometrium (Rubin et al., <xref ref-type="bibr" rid="B118">1999</xref>), SULT2B1 is the major DHEA-specific SULT enzyme in endometrial cancer, and increased <italic>SULT2B1</italic> expression has recently been reported in endometrial cancer, compared to adjacent control endometrium (Hevir et al., <xref ref-type="bibr" rid="B54">2011</xref>). Also Human Protein Atlas data show medium to high staining of cancerous endometrium with two different anti-SULT2B1 antibodies (Uhlén et al., <xref ref-type="bibr" rid="B139">2015</xref>), which further supports the conclusion that despite of increased DHEA-S STS activity, DHEA-S may not represent the steroid precursor for E2 formation in cancerous endometrium.</p>
<p>Although the expression of the <italic>STS</italic> and <italic>SULT1E1</italic> genes in diseased vs. control endometrium has differed between studies (Table <xref ref-type="table" rid="T6">6</xref>), all of the published data show higher mRNA and protein levels for <italic>STS</italic> than <italic>SULT1E1</italic> in endometrial cancer tissue vs. control endometrium. The majority of the published data also shows increased E1-S STS activity in endometrial cancer, and thus supports E2 formation via the STS pathway.</p>
</sec>
<sec>
<title>Sulfatase and sulfotransferase in ovarian cancer</title>
<p>Ovarian cancer is the sixth leading cause of cancer-related death in the developed world. Worldwide, there were 238,719 new cases and 151,905 deaths estimated for 2012 (Ferlay et al., <xref ref-type="bibr" rid="B35">2013</xref>). Most patients are diagnosed when they show advanced stage disease with poor prognosis. Ovarian cancer is a heterogeneous disease that encompasses several types of tumors, with large differences in histopathological features and clinical behaviors. Epithelial ovarian cancers are the most frequent tumors, which account for around 98% of all cases. These can be defined into distinct diseases, as serous (75%), endometrioid (10%), clear-cell (5–10%), and mucinous (5–10%) ovarian cancers, which are usually grouped into low-grade or high-grade tumors (Guarneri et al., <xref ref-type="bibr" rid="B48">2011</xref>). Nowadays, it is widely accepted that serous, mucinous, endometrioid, clear cell, and other histotypes of ovarian cancers represent molecularly and etiologically distinct diseases (Vaughan et al., <xref ref-type="bibr" rid="B143">2011</xref>). The etiology of ovarian cancer can be explained by the “incessant ovulation theory” and the “gonadotropin theory” (Stadel, <xref ref-type="bibr" rid="B128">1975</xref>; Fathalla, <xref ref-type="bibr" rid="B33">2013</xref>). An increasing body of data suggests that ovarian cancer is estrogen dependent, although the role of estrogens in this disease has not yet been investigated thoroughly (Chura et al., <xref ref-type="bibr" rid="B19">2009</xref>). Genetic susceptibility studies have associated SNPs in the <italic>ESR2</italic> gene that codes for ERβ with significantly increased risk of ovarian cancer (Lurie et al., <xref ref-type="bibr" rid="B77">2011</xref>), and epidemiological studies (Women's Health Initiative and Million Women Studies: (Anderson et al., <xref ref-type="bibr" rid="B6">2003</xref>; Beral et al., <xref ref-type="bibr" rid="B7">2007</xref>) have also suggested that both estrogen only and estrogen–progestin hormone replacement therapies increase the risk of ovarian cancer (Modugno et al., <xref ref-type="bibr" rid="B87">2012</xref>). However, the current lack of knowledge warrants further studies on the mechanisms of steroid hormone actions in ovarian cancer, followed by clinical trials that may also target estrogen actions.</p>
<p>The expression of STS has been studied at the mRNA and protein levels (Table <xref ref-type="table" rid="T7">7</xref>). No significant differences were reported between epithelial ovarian carcinoma and ovarian surface epithelia tissue and primary cell cultures at the mRNA and protein levels (Ren et al., <xref ref-type="bibr" rid="B114">2015</xref>). However, Okuda et al. detected STS staining in 70% of ovarian clear-cell adenocarcinoma, 33% of serous adenocarcinoma and 50% of mucinous adenocarcinoma, thus suggesting the importance of STS in this pathophysiology (Okuda et al., <xref ref-type="bibr" rid="B96">2001</xref>). In contrast to these data, the Human Protein Atlas reports low to medium expression of STS in only two samples of mucinous adenocarcinoma out of 12 serous, mucinous and endometrioid ovarian cancer samples (Uhlén et al., <xref ref-type="bibr" rid="B139">2015</xref>). The STS activity has been studied by two groups: Ren et al. reported higher activity in the SKOV-3 and PEO epithelial ovarian carcinoma cell lines vs. the OSE normal ovarian surface epithelium cell line (Ren et al., <xref ref-type="bibr" rid="B114">2015</xref>), and Chura et al. reported correlations between increased STS activity and lower progression-free survival of patients (Chura et al., <xref ref-type="bibr" rid="B19">2009</xref>).</p>
<table-wrap id="T7" position="float">
<label>Table 7</label>
<caption>
<p><bold>Expression of STS and SULTs in ovarian cancer</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Level</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Regulation</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>STS</italic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">mRNA</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">≈ EOC/OSE</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Ren et al., <xref ref-type="bibr" rid="B114">2015</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Protein</td>
<td align="left" colspan="1" rowspan="1" valign="top">Expressed EOC and OSE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ren et al., <xref ref-type="bibr" rid="B114">2015</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">70% OCCA; 33% serous and 50% mucinous adenocarcinoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">Okuda et al., <xref ref-type="bibr" rid="B96">2001</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1" style="border-bottom: thin solid #000000;"></td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">17% Cancer low/moderate Normal ovary low (stromal cells)</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Human Protein Atlas</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Activity (E1-S)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> SKOV-3, PEO-1 vs. OSE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ren et al., <xref ref-type="bibr" rid="B114">2015</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0001.jpg"></inline-graphic> STS <inline-graphic xlink:href="fphar-07-00030-i0002.jpg"></inline-graphic> progression-free survival</td>
<td align="left" colspan="1" rowspan="1" valign="top">Chura et al., <xref ref-type="bibr" rid="B19">2009</xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SULT1E1</italic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">mRNA</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0002.jpg"></inline-graphic> EOC/OSE</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Ren et al., <xref ref-type="bibr" rid="B114">2015</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Protein</td>
<td align="left" colspan="1" rowspan="1" valign="top">Expressed EOC and OSE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ren et al., <xref ref-type="bibr" rid="B114">2015</xref></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1" style="border-bottom: thin solid #000000;"></td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">17% Cancer moderate/normal ND</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">Human Protein Atlas</td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Activity (E1)</td>
<td align="left" colspan="1" rowspan="1" valign="top"><inline-graphic xlink:href="fphar-07-00030-i0002.jpg"></inline-graphic> SKOV-3, PEO-1 vs. OSE</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ren et al., <xref ref-type="bibr" rid="B114">2015</xref></td>
</tr>
<tr style="border-bottom: thin solid #000000;">
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SULT2A1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Protein</td>
<td align="left" colspan="1" rowspan="1" valign="top">17%-50% Cancer low/moderate Normal ovary/ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">Human Protein Atlas</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">
<italic>SULT2B1</italic>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Protein</td>
<td align="left" colspan="1" rowspan="1" valign="top">58%-100% Cancer moderate Normal ovary/weak</td>
<td align="left" colspan="1" rowspan="1" valign="top">Human Protein Atlas</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>EOC, epithelial ovarian carcinoma; OSE, ovarian surface epithelia; OCCA, ovarian clear-cell adenocarcinoma</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>The expression of the <italic>SULT1E1</italic> gene has only been investigated by one group (Ren et al., <xref ref-type="bibr" rid="B114">2015</xref>; Table <xref ref-type="table" rid="T7">7</xref>). They reported that <italic>SULT1E1</italic> expression was down-regulated in epithelial ovarian carcinoma vs. the OSE normal ovarian surface epithelium cell line, and also that SULT activity was lower in SKOV-3 and PEO cells vs. OSE cells. This all supports the importance of local estrogen formation via the STS pathway (Ren et al., <xref ref-type="bibr" rid="B114">2015</xref>). Using three different anti-SULT1E1 antibodies, SULT1E1 was detected in two of 12 cores of ovarian cancer, with low to high staining observed mainly in mucinous ovarian cancer (Uhlén et al., <xref ref-type="bibr" rid="B139">2015</xref>). With two polyclonal anti-SULT2A1 antibodies, SULT2A1 was detected in two to six of 12 cores, with low to medium intensity, while with three different anti-SULT2B1 antibodies, medium to high intensity staining was reported for SULT2B1 in seven to 12 of 12 tissue microarray cores (Uhlén et al., <xref ref-type="bibr" rid="B139">2015</xref>). To date, there have been no other reports on the expression of SULT2A1 and SULT2B1 in ovarian cancer. Based on these data, DHEA-S cannot be excluded as a potential precursor molecule for local estrogen formation in ovarian cancer.</p>
</sec>
</sec>
<sec id="s5">
<title>Sulfatase as a target for treatment of gynecological disease</title>
<p>There is a plethora of data that supports the important role of STS in individual gynecological diseases, with disturbances reported for the balance between the STS and SULT enzymes. Although the observed STS mRNA and protein levels were rarely increased, higher STS activities have been seen in the majority of pathological tissues and in model cell lines, including cancerous endometrium (Adessi et al., <xref ref-type="bibr" rid="B2">1984</xref>; Prost et al., <xref ref-type="bibr" rid="B105">1984</xref>; Naitoh et al., <xref ref-type="bibr" rid="B92">1989</xref>; Urabe et al., <xref ref-type="bibr" rid="B140">1989</xref>; Day et al., <xref ref-type="bibr" rid="B24">2009</xref>), ovarian cancer cell lines (Day et al., <xref ref-type="bibr" rid="B24">2009</xref>; Ren et al., <xref ref-type="bibr" rid="B114">2015</xref>), and adenomyosis (Yamamoto et al., <xref ref-type="bibr" rid="B148">1993</xref>; Ezaki et al., <xref ref-type="bibr" rid="B29">2001</xref>). This is in line with the higher catalytic efficiency of STS vs. SULT (Table <xref ref-type="table" rid="T1">1</xref>), and in some cases, higher expression levels of <italic>STS</italic> (Tables <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T6">6</xref>). Furthermore, in endometriosis, endometrial cancer, and ovarian cancer, the STS pathway has been shown to prevail over the aromatase pathway (Purohit et al., <xref ref-type="bibr" rid="B106">2008</xref>; Fournier and Poirier, <xref ref-type="bibr" rid="B39">2009</xref>; Hevir-Kene and Rižner, <xref ref-type="bibr" rid="B55">2015</xref>; Ren et al., <xref ref-type="bibr" rid="B114">2015</xref>), which substantiate the potential of STS as a drug target.</p>
<p>Lack of correlation between STS mRNA levels and STS activity imply that post-translational modifications might increase STS activity. Additionally, increased uptake and decreased excretion of the sulfated steroids might also be recognized as enhanced STS activity, which would explain why RNA levels are less informative (Newman et al., <xref ref-type="bibr" rid="B95">2000</xref>). As not much is known about the transport of E1-S and DHEA-S across the plasma membrane in these diseased tissues, their uptake and excretion should be studied, as this will help us to better understand local estrogen formation and actions.</p>
</sec>
<sec id="s6">
<title>Sulfatase inhibitors and clinical trials</title>
<p>The development of STS inhibitors started in the 1990s, and to date, this has led to two compounds that have entered clinical trials (Poirier, <xref ref-type="bibr" rid="B103">2015</xref>). STS inhibitors have been developed by several research groups and several pharmaceutical companies, and the current status of this field has been a topic of several educative reviews in the last few years (Mostafa and Taylor, <xref ref-type="bibr" rid="B89">2013</xref>; Sadozai, <xref ref-type="bibr" rid="B120">2013</xref>; Thomas and Potter, <xref ref-type="bibr" rid="B134">2013</xref>, <xref ref-type="bibr" rid="B135">2015</xref>; Williams, <xref ref-type="bibr" rid="B145">2013</xref>; Poirier, <xref ref-type="bibr" rid="B103">2015</xref>). In general, the large number of STS inhibitors known to date can be divided into steroidal and nonsteroidal compounds, and further into sulfomoylated and nonsulfomoylated compounds (Maltais and Poirier, <xref ref-type="bibr" rid="B82">2011</xref>). Among the steroidal compounds, estrogen O-sulfamates have been the most intensively studied in <italic>in-vitro</italic> and <italic>in-vivo</italic> models. These have included E1-3-O-sulfamate (EMATE) and E2-3-O-sulfamate (E2MATE), where EMATE was identified as the first irreversible STS inhibitor, although it was originally developed as a prodrug for estrogen replacement therapy (Sadozai, <xref ref-type="bibr" rid="B120">2013</xref>; Thomas and Potter, <xref ref-type="bibr" rid="B135">2015</xref>).</p>
<p>Nonsteroidal inhibitors have also been developed, and an irreversible STS inhibitor, 667 Coumate (also known as STX64 and BN83495, and more recently referred to as irosustat), shows higher potency than EMATE (IC<sub>50</sub>, 8 nM vs. 25 nM, at 20 μM E1-S, against STS from placental microsomes) (Woo et al., <xref ref-type="bibr" rid="B146">2000</xref>). This compound has high bioavailability, which was explained by its sequestration within erythrocytes, where it binds to carbonic anhydrase II (IC<sub>50</sub>, 25 nM) (Ho et al., <xref ref-type="bibr" rid="B58">2003</xref>). A plethora of EMATE and 667 Coumate derivatives have been developed in the last few years as 2nd and 3rd generation STS inhibitors (Sadozai, <xref ref-type="bibr" rid="B120">2013</xref>; Thomas and Potter, <xref ref-type="bibr" rid="B135">2015</xref>). These have included the steroidal compound KW-2581 that showed no estrogenic activity (Ishida et al., <xref ref-type="bibr" rid="B62">2007</xref>), and STX213 and STX1938, which have shown greater potency than 667 Coumate (Foster et al., <xref ref-type="bibr" rid="B37">2008b</xref>).</p>
<p>In addition to classical STS inhibitors, dual inhibitors that target STS and aromatase have also been developed (Sadozai, <xref ref-type="bibr" rid="B120">2013</xref>), as well as compounds with dual actions as STS inhibitors and prodrugs of selective estrogen modulators (Sadozai, <xref ref-type="bibr" rid="B120">2013</xref>). Here, the nonsteroidal dual aromatase–STS inhibitor STX681 has shown great potential for treatment of hormone-dependent breast cancer (Foster et al., <xref ref-type="bibr" rid="B36">2008a</xref>), and the dual sulfamate STS inhibitor and antiestrogen SR16157 has also been studied (Rasmussen et al., <xref ref-type="bibr" rid="B110">2007</xref>; Sadozai, <xref ref-type="bibr" rid="B120">2013</xref>).</p>
<p>The published data imply that inhibitors of STS have the potential for treatment of individual gynecological diseases. In the case of endometriosis, STS activity correlates with the severity of this disease, and Purohit et al. reported that the STS inhibitor STX64 almost completely blocked STS activity <italic>in vitro</italic> in eutopic and ectopic tissue from patients with peritoneal endometriosis (Purohit et al., <xref ref-type="bibr" rid="B106">2008</xref>). Furthermore, E2MATE inhibited STS activity in endometrial tissue <italic>in vitro</italic> and <italic>in vivo</italic> in animal models, including in mouse uterus, liver, leukocytes and endometriotic lesions (Colette et al., <xref ref-type="bibr" rid="B20">2011</xref>). Also, the inhibitor STX64 has been investigated in intact mouse endometrial cancer xenografts and ovariectomized mouse endometrial cancer xenograft models, and in the latter case, STX64 showed significant inhibition after daily 1–10 mg/kg oral doses (Foster et al., <xref ref-type="bibr" rid="B38">2008c</xref>), thus demonstrating the great potential of STS inhibitors as novel anticancer drugs. To the best of our knowledge, STS inhibitors have not yet been investigated in ovarian cancer, adenomyosis and myoma uteri, neither <italic>in vitro</italic> nor <italic>in vivo</italic>.</p>
<p>Several clinical studies have already been performed with STS inhibitors (Thomas and Potter, <xref ref-type="bibr" rid="B135">2015</xref>). Irosustat (i.e., 667 Coumate) was the first STS inhibitor to enter phase I clinical trials, in post-menopausal women with ER-positive breast cancer (NCT01840488); (Stanway et al., <xref ref-type="bibr" rid="B129">2006</xref>). Later, two phase II clinical studies were reported in breast cancer patients (ClinicalTrials.gov): the IPET trial was designed to look at the effects of irosustat using positron emission tomography scanning (Thomas and Potter, <xref ref-type="bibr" rid="B135">2015</xref>), while the IRIS trial investigated the effects of combined treatment with irosustat and anastrozole (an aromatase inhibitor) (NCT01785992). Unfortunately no study data are publicly available for these trials.</p>
<p>Irosustat has also been investigated in ER-positive advanced/recurrent endometrial cancer in a phase II study (NCT00910091). In this study, irosustat was evaluated vs. progestin megestrol acetate in 73 patients, with median age 68 years (range, 37–85 years). Here, 36 patients were randomized to irosustat (40 mg/day), and 37 to megestrol acetate (160 mg/day) (Pautier et al., <xref ref-type="bibr" rid="B100">2012</xref>). After 6 months of treatment, 36.1 and 56.8% of the patients treated with irosustat and megestrol acetate, respectively, were alive and without disease progression. Progression free survival was 16 and 32 weeks for irosustat and megestrol acetate, respectively. Thus, in patients with advanced and recurrent disease, irosustat showed much lower clinical benefit compared to progestin megestrol acetate, which questioned the suitability of STS inhibitors for treatment of endometrial cancer.</p>
<p>In a murine model, E2MATE reduced the weight of the endometriotic lesions, but had no effects on proliferation and apoptosis, or on STS expression (Colette et al., <xref ref-type="bibr" rid="B20">2011</xref>), which led the Swiss-based biopharmaceutical company PregLem to investigate E2MATE in endometriosis patients. As described by Pohl et al. they first examined the effects of E2MATE in a phase I study (SAPHIR; EudraCT number: 2007-005662-12) in healthy women of reproductive age, through which they showed that E2MATE can inhibit STS in peripheral blood mononuclear cells, although it failed to inhibit STS in eutopic endometrium (Pohl et al., <xref ref-type="bibr" rid="B102">2014</xref>). As a continuation, they investigated the effects of E2MATE (4 mg/week) and/or norethindrone acetate (NETA; 10 mg/day) in healthy nonpregnant women of reproductive age (i.e., 24–39 years). Twenty-four women were randomized to E2MATE, NETA or the combination E2MATE+NETA, for 4 weeks of treatment and 12 weeks of follow-up. In both the E2MATE and E2MATE+NETA groups, the STS activity in peripheral blood mononuclear cells and in the endometrium decreased by 90–91% and 89–96%, respectively, during treatment, and these inhibition levels remained high also 1 month after the treatments (Pohl et al., <xref ref-type="bibr" rid="B102">2014</xref>). E2MATE and NETA have been further studied in endometriosis patients in a phase II study (EudraCT Number: 2011-005167-24), although at present, no results are publicly available.</p>
</sec>
<sec id="s7">
<title>Conclusions and perspectives</title>
<p>The STS pathway is clearly implicated in local estrogen formation, and is thus also associated with enhanced estrogen actions. A vast amount of data supports an important role for STS in hormone-dependent diseases, including gynecological diseases like endometrial cancer, ovarian cancer, endometriosis, and adenomyosis, and indirectly also in uterine fibroids. However, the clinical studies that have evaluated STS inhibitors in gynecological diseases to date have not provided convincing data. Although the dual STS and aromatase inhibitors and dual action inhibitors/antiestrogens might provide better clinical performances compared to the classical STS inhibitors, these agents have not reached clinical studies to date. As the intricate local estrogen formation also depends on membrane transport of the sulfated steroids, this aspect needs to be investigated more in detail. This knowledge might contribute to a logical interpretation of the clinical studies to date, and might lead to the identification of novel drug targets and combined treatments that will target individual transporters and the STS enzyme.</p>
</sec>
<sec id="s8">
<title>Author contributions</title>
<p>The author confirms being the sole contributor of this work and approved it for publication.</p>
<sec>
<title>Conflict of interest statement</title>
<p>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>The writing of this manuscript was supported by grants J3-5510 and J3-6799 from the Slovenian Research Agency to the author.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abulafia</surname><given-names>O.</given-names></name><name><surname>Lee</surname><given-names>Y. C.</given-names></name><name><surname>Wagreich</surname><given-names>A.</given-names></name><name><surname>Economos</surname><given-names>K.</given-names></name><name><surname>Serur</surname><given-names>E.</given-names></name><name><surname>Nacharaju</surname><given-names>V. L.</given-names></name></person-group> (<year>2009</year>). <article-title>Sulfatase activity in normal and neoplastic endometrium</article-title>. <source/>Gynecol. Obstet. Invest.
<volume>67</volume>, <fpage>57</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1159/000161571</pub-id><pub-id pub-id-type="pmid">18843186</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adessi</surname><given-names>G. L.</given-names></name><name><surname>Prost</surname><given-names>O.</given-names></name><name><surname>Agnani</surname><given-names>G.</given-names></name><name><surname>Petitjean</surname><given-names>A.</given-names></name><name><surname>Burnod</surname><given-names>J.</given-names></name></person-group> (<year>1984</year>). <article-title>Estrone sulfatase activity in normal and abnormal endometrium</article-title>. <source/>Arch. Gynecol.
<volume>236</volume>, <fpage>13</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1007/BF02114864</pub-id><pub-id pub-id-type="pmid">6508360</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adjei</surname><given-names>A. A.</given-names></name><name><surname>Thomae</surname><given-names>B. A.</given-names></name><name><surname>Prondzinski</surname><given-names>J. L.</given-names></name><name><surname>Eckloff</surname><given-names>B. W.</given-names></name><name><surname>Wieben</surname><given-names>E. D.</given-names></name><name><surname>Weinshilboum</surname><given-names>R. M.</given-names></name></person-group> (<year>2003</year>). <article-title>Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics</article-title>. <source/>Br. J. Pharmacol.
<volume>139</volume>, <fpage>1373</fpage>–<lpage>1382</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0705369</pub-id><pub-id pub-id-type="pmid">12922923</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhmedkhanov</surname><given-names>A.</given-names></name><name><surname>Zeleniuch-Jacquotte</surname><given-names>A.</given-names></name><name><surname>Toniolo</surname><given-names>P.</given-names></name></person-group> (<year>2001</year>). <article-title>Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives</article-title>. <source/>Ann. N.Y. Acad. Sci.
<volume>943</volume>, <fpage>296</fpage>–<lpage>315</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2001.tb03811.x</pub-id><pub-id pub-id-type="pmid">11594550</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amant</surname><given-names>F.</given-names></name><name><surname>Moerman</surname><given-names>P.</given-names></name><name><surname>Neven</surname><given-names>P.</given-names></name><name><surname>Timmerman</surname><given-names>D.</given-names></name><name><surname>Van Limbergen</surname><given-names>E.</given-names></name><name><surname>Vergote</surname><given-names>I.</given-names></name></person-group> (<year>2005</year>). <article-title>Endometrial cancer</article-title>. <source/>Lancet
<volume>366</volume>, <fpage>491</fpage>–<lpage>505</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(05)67063-8</pub-id><pub-id pub-id-type="pmid">16084259</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>G. L.</given-names></name><name><surname>Judd</surname><given-names>H. L.</given-names></name><name><surname>Kaunitz</surname><given-names>A. M.</given-names></name><name><surname>Barad</surname><given-names>D. H.</given-names></name><name><surname>Beresford</surname><given-names>S. A.</given-names></name><name><surname>Pettinger</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial</article-title>. <source/>JAMA
<volume>290</volume>, <fpage>1739</fpage>–<lpage>1748</lpage>. <pub-id pub-id-type="doi">10.1001/jama.290.13.1739</pub-id><pub-id pub-id-type="pmid">14519708</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beral</surname><given-names>V.</given-names></name><name><surname>Bull</surname><given-names>D.</given-names></name><name><surname>Green</surname><given-names>J.</given-names></name><name><surname>Reeves</surname><given-names>G.</given-names></name><name><surname>Collaborators</surname><given-names>M. W. S.</given-names></name></person-group> (<year>2007</year>). <article-title>Ovarian cancer and hormone replacement therapy in the Million Women Study</article-title>. <source/>Lancet
<volume>369</volume>, <fpage>1703</fpage>–<lpage>1710</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60534-0</pub-id><pub-id pub-id-type="pmid">17512855</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berstein</surname><given-names>L. M.</given-names></name><name><surname>Tchernobrovkina</surname><given-names>A. E.</given-names></name><name><surname>Gamajunova</surname><given-names>V. B.</given-names></name><name><surname>Kovalevskij</surname><given-names>A. J.</given-names></name><name><surname>Vasilyev</surname><given-names>D. A.</given-names></name><name><surname>Chepik</surname><given-names>O. F.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer</article-title>. <source/>J. Cancer Res. Clin. Oncol.
<volume>129</volume>, <fpage>245</fpage>–<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1007/s00432-003-0427-9</pub-id><pub-id pub-id-type="pmid">12695909</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonney</surname><given-names>R. C.</given-names></name><name><surname>Scanlon</surname><given-names>M. J.</given-names></name><name><surname>Jones</surname><given-names>D. L.</given-names></name><name><surname>Reed</surname><given-names>M. J.</given-names></name><name><surname>Anderson</surname><given-names>M. C.</given-names></name><name><surname>James</surname><given-names>V. H.</given-names></name></person-group> (<year>1986</year>). <article-title>The relationship between oestradiol metabolism and adrenal steroids in the endometrium of postmenopausal women with and without endometrial cancer</article-title>. <source/>Eur. J. Cancer Clin. Oncol.
<volume>22</volume>, <fpage>953</fpage>–<lpage>961</lpage>. <pub-id pub-id-type="doi">10.1016/0277-5379(86)90062-3</pub-id><pub-id pub-id-type="pmid">3021469</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borghese</surname><given-names>B.</given-names></name><name><surname>Mondon</surname><given-names>F.</given-names></name><name><surname>Noël</surname><given-names>J. C.</given-names></name><name><surname>Fayt</surname><given-names>I.</given-names></name><name><surname>Mignot</surname><given-names>T. M.</given-names></name><name><surname>Vaiman</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Gene expression profile for ectopic versus eutopic endometrium provides new insights into endometriosis oncogenic potential</article-title>. <source/>Mol. Endocrinol.
<volume>22</volume>, <fpage>2557</fpage>–<lpage>2562</lpage>. <pub-id pub-id-type="doi">10.1210/me.2008-0322</pub-id><pub-id pub-id-type="pmid">18818281</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brookes</surname><given-names>K. J.</given-names></name><name><surname>Hawi</surname><given-names>Z.</given-names></name><name><surname>Park</surname><given-names>J.</given-names></name><name><surname>Scott</surname><given-names>S.</given-names></name><name><surname>Gill</surname><given-names>M.</given-names></name><name><surname>Kent</surname><given-names>L.</given-names></name></person-group> (<year>2010</year>). <article-title>Polymorphisms of the steroid sulfatase (STS) gene are associated with attention deficit hyperactivity disorder and influence brain tissue mRNA expression</article-title>. <source/>Am. J. Med. Genet. B Neuropsychiatr. Genet.
<volume>153B</volume>, <fpage>1417</fpage>–<lpage>1424</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.b.31120</pub-id><pub-id pub-id-type="pmid">20862695</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brosens</surname><given-names>I.</given-names></name><name><surname>Benagiano</surname><given-names>G.</given-names></name></person-group> (<year>2011</year>). <article-title>Endometriosis, a modern syndrome</article-title>. <source/>Indian J. Med. Res.
<volume>133</volume>, <fpage>581</fpage>–<lpage>593</lpage>. <pub-id pub-id-type="pmid">21727656</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulun</surname><given-names>S. E.</given-names></name></person-group> (<year>2013</year>). <article-title>Uterine fibroids</article-title>. <source/>N. Engl. J. Med.
<volume>369</volume>, <fpage>1344</fpage>–<lpage>1355</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1209993</pub-id><pub-id pub-id-type="pmid">24088094</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burney</surname><given-names>R. O.</given-names></name><name><surname>Talbi</surname><given-names>S.</given-names></name><name><surname>Hamilton</surname><given-names>A. E.</given-names></name><name><surname>Vo</surname><given-names>K. C.</given-names></name><name><surname>Nyegaard</surname><given-names>M.</given-names></name><name><surname>Nezhat</surname><given-names>C. R.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis</article-title>. <source/>Endocrinology
<volume>148</volume>, <fpage>3814</fpage>–<lpage>3826</lpage>. <pub-id pub-id-type="doi">10.1210/en.2006-1692</pub-id><pub-id pub-id-type="pmid">17510236</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlström</surname><given-names>K.</given-names></name><name><surname>Bergqvist</surname><given-names>A.</given-names></name><name><surname>Ljungberg</surname><given-names>O.</given-names></name></person-group> (<year>1988</year>). <article-title>Metabolism of estrone sulfate in endometriotic tissue and in uterine endometrium in proliferative and secretory cycle phase</article-title>. <source/>Fertil. Steril.
<volume>49</volume>, <fpage>229</fpage>–<lpage>233</lpage>. <pub-id pub-id-type="pmid">2828122</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caron</surname><given-names>P.</given-names></name><name><surname>Audet-Walsh</surname><given-names>E.</given-names></name><name><surname>Lépine</surname><given-names>J.</given-names></name><name><surname>Bélanger</surname><given-names>A.</given-names></name><name><surname>Guillemette</surname><given-names>C.</given-names></name></person-group> (<year>2009</year>). <article-title>Profiling endogenous serum estrogen and estrogen-glucuronides by liquid chromatography-tandem mass spectrometry</article-title>. <source/>Anal. Chem.
<volume>81</volume>, <fpage>10143</fpage>–<lpage>10148</lpage>. <pub-id pub-id-type="doi">10.1021/ac9019126</pub-id><pub-id pub-id-type="pmid">19916521</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chetrite</surname><given-names>G. S.</given-names></name><name><surname>Cortes-Prieto</surname><given-names>J.</given-names></name><name><surname>Philippe</surname><given-names>J. C.</given-names></name><name><surname>Wright</surname><given-names>F.</given-names></name><name><surname>Pasqualini</surname><given-names>J. R.</given-names></name></person-group> (<year>2000</year>). <article-title>Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>72</volume>, <fpage>23</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/S0960-0760(00)00040-6</pub-id><pub-id pub-id-type="pmid">10731634</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J. Y.</given-names></name><name><surname>Lee</surname><given-names>K. M.</given-names></name><name><surname>Park</surname><given-names>S. K.</given-names></name><name><surname>Noh</surname><given-names>D. Y.</given-names></name><name><surname>Ahn</surname><given-names>S. H.</given-names></name><name><surname>Chung</surname><given-names>H. W.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer</article-title>. <source/>Cancer Epidemiol. Biomarkers Prev.
<volume>14</volume>, <fpage>1090</fpage>–<lpage>1095</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-04-0688</pub-id><pub-id pub-id-type="pmid">15894657</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chura</surname><given-names>J. C.</given-names></name><name><surname>Blomquist</surname><given-names>C. H.</given-names></name><name><surname>Ryu</surname><given-names>H. S.</given-names></name><name><surname>Argenta</surname><given-names>P. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Estrone sulfatase activity in patients with advanced ovarian cancer</article-title>. <source/>Gynecol. Oncol.
<volume>112</volume>, <fpage>205</fpage>–<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2008.08.037</pub-id><pub-id pub-id-type="pmid">18947862</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colette</surname><given-names>S.</given-names></name><name><surname>Defrère</surname><given-names>S.</given-names></name><name><surname>Lousse</surname><given-names>J. C.</given-names></name><name><surname>Van Langendonckt</surname><given-names>A.</given-names></name><name><surname>Gotteland</surname><given-names>J. P.</given-names></name><name><surname>Loumaye</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Inhibition of steroid sulfatase decreases endometriosis in an <italic>in vivo</italic> murine model</article-title>. <source/>Hum. Reprod.
<volume>26</volume>, <fpage>1362</fpage>–<lpage>1370</lpage>. <pub-id pub-id-type="doi">10.1093/humrep/der079</pub-id><pub-id pub-id-type="pmid">21441545</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colette</surname><given-names>S.</given-names></name><name><surname>Defrère</surname><given-names>S.</given-names></name><name><surname>Van Kerk</surname><given-names>O.</given-names></name><name><surname>Van Langendonckt</surname><given-names>A.</given-names></name><name><surname>Dolmans</surname><given-names>M. M.</given-names></name><name><surname>Donnez</surname><given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>Differential expression of steroidogenic enzymes according to endometriosis type</article-title>. <source/>Fertil. Steril.
<volume>100</volume>, <fpage>1642</fpage>–<lpage>1649</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2013.08.003</pub-id><pub-id pub-id-type="pmid">24012197</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coughtrie</surname><given-names>M. W.</given-names></name></person-group> (<year>2002</year>). <article-title>Sulfation through the looking glass–recent advances in sulfotransferase research for the curious</article-title>. <source/>Pharmacogenomics J.
<volume>2</volume>, <fpage>297</fpage>–<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1038/sj.tpj.6500117</pub-id><pub-id pub-id-type="pmid">12439736</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dassen</surname><given-names>H.</given-names></name><name><surname>Punyadeera</surname><given-names>C.</given-names></name><name><surname>Kamps</surname><given-names>R.</given-names></name><name><surname>Delvoux</surname><given-names>B.</given-names></name><name><surname>Van Langendonckt</surname><given-names>A.</given-names></name><name><surname>Donnez</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Estrogen metabolizing enzymes in endometrium and endometriosis</article-title>. <source/>Hum. Reprod.
<volume>22</volume>, <fpage>3148</fpage>–<lpage>3158</lpage>. <pub-id pub-id-type="doi">10.1093/humrep/dem310</pub-id><pub-id pub-id-type="pmid">17921479</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>J. M.</given-names></name><name><surname>Purohit</surname><given-names>A.</given-names></name><name><surname>Tutill</surname><given-names>H. J.</given-names></name><name><surname>Foster</surname><given-names>P. A.</given-names></name><name><surname>Woo</surname><given-names>L. W.</given-names></name><name><surname>Potter</surname><given-names>B. V.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy</article-title>. <source/>Ann. N.Y. Acad. Sci.
<volume>1155</volume>, <fpage>80</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2008.03677.x</pub-id><pub-id pub-id-type="pmid">19250195</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delvoux</surname><given-names>B.</given-names></name><name><surname>Groothuis</surname><given-names>P.</given-names></name><name><surname>D'Hooghe</surname><given-names>T.</given-names></name><name><surname>Kyama</surname><given-names>C.</given-names></name><name><surname>Dunselman</surname><given-names>G.</given-names></name><name><surname>Romano</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Increased production of 17beta-estradiol in endometriosis lesions is the result of impaired metabolism</article-title>. <source/>J. Clin. Endocrinol. Metab.
<volume>94</volume>, <fpage>876</fpage>–<lpage>883</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2008-2218</pub-id><pub-id pub-id-type="pmid">19088158</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duanmu</surname><given-names>Z.</given-names></name><name><surname>Kocarek</surname><given-names>T.</given-names></name><name><surname>Runge-Morris</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Regulation of human hepatic estrogen sulfotransferase (SULT1E1) expression by xenobiotics and lipid intermediates</article-title>. <source/>FASEB J.
<volume>21</volume>, <fpage>886</fpage>.19.</mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Echchgadda</surname><given-names>I.</given-names></name><name><surname>Song</surname><given-names>C. S.</given-names></name><name><surname>Oh</surname><given-names>T.</given-names></name><name><surname>Ahmed</surname><given-names>M.</given-names></name><name><surname>De La Cruz</surname><given-names>I. J.</given-names></name><name><surname>Chatterjee</surname><given-names>B.</given-names></name></person-group> (<year>2007</year>). <article-title>The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4alpha in the regulation of human steroid-/bile acid-sulfotransferase</article-title>. <source/>Mol. Endocrinol.
<volume>21</volume>, <fpage>2099</fpage>–<lpage>2111</lpage>. <pub-id pub-id-type="doi">10.1210/me.2007-0002</pub-id><pub-id pub-id-type="pmid">17595319</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>P. M.</given-names></name><name><surname>Williams</surname><given-names>M. L.</given-names></name><name><surname>Choi</surname><given-names>E. H.</given-names></name><name><surname>Feingold</surname><given-names>K. R.</given-names></name></person-group> (<year>2014</year>). <article-title>Role of cholesterol sulfate in epidermal structure and function: lessons from X-linked ichthyosis</article-title>. <source/>Biochim. Biophys. Acta
<volume>1841</volume>, <fpage>353</fpage>–<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbalip.2013.11.009</pub-id><pub-id pub-id-type="pmid">24291327</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezaki</surname><given-names>K.</given-names></name><name><surname>Motoyama</surname><given-names>H.</given-names></name><name><surname>Sasaki</surname><given-names>H.</given-names></name></person-group> (<year>2001</year>). <article-title>Immunohistologic localization of estrone sulfatase in uterine endometrium and adenomyosis</article-title>. <source/>Obstet. Gynecol. <volume>98</volume>(<issue>5 Pt 1</issue>), <fpage>815</fpage>–<lpage>819</lpage>. <pub-id pub-id-type="doi">10.1016/S0029-7844(01)01554-X</pub-id><pub-id pub-id-type="pmid">11704174</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falany</surname><given-names>C. N.</given-names></name><name><surname>Krasnykh</surname><given-names>V.</given-names></name><name><surname>Falany</surname><given-names>J. L.</given-names></name></person-group> (<year>1995</year>). <article-title>Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>52</volume>, <fpage>529</fpage>–<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1016/0960-0760(95)00015-R</pub-id><pub-id pub-id-type="pmid">7779757</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falany</surname><given-names>J. L.</given-names></name><name><surname>Falany</surname><given-names>C. N.</given-names></name></person-group> (<year>1996</year>). <article-title>Regulation of estrogen sulfotransferase in human endometrial adenocarcinoma cells by progesterone</article-title>. <source/>Endocrinology
<volume>137</volume>, <fpage>1395</fpage>–<lpage>1401</lpage>. <pub-id pub-id-type="pmid">8625916</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falany</surname><given-names>J. L.</given-names></name><name><surname>Falany</surname><given-names>C. N.</given-names></name></person-group> (<year>2006</year>). <article-title>Regulation of SULT1E1 expression in Ishikawa adenocarcinoma cells by tibolone</article-title>. <source/>Steroids
<volume>71</volume>, <fpage>880</fpage>–<lpage>885</lpage>. <pub-id pub-id-type="doi">10.1016/j.steroids.2006.05.018</pub-id><pub-id pub-id-type="pmid">16857224</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fathalla</surname><given-names>M. F.</given-names></name></person-group> (<year>2013</year>). <article-title>Incessant ovulation and ovarian cancer - a hypothesis re-visited</article-title>. <source/>Facts Views Vis. Obgyn.
<volume>5</volume>, <fpage>292</fpage>–<lpage>297</lpage>. <pub-id pub-id-type="pmid">24753957</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fechner</surname><given-names>S.</given-names></name><name><surname>Husen</surname><given-names>B.</given-names></name><name><surname>Thole</surname><given-names>H.</given-names></name><name><surname>Schmidt</surname><given-names>M.</given-names></name><name><surname>Gashaw</surname><given-names>I.</given-names></name><name><surname>Kimmig</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Expression and regulation of estrogen-converting enzymes in ectopic human endometrial tissue</article-title>. <source/>Fertil. Steril. <volume>88</volume>(<issue>4 Suppl.</issue>), <fpage>1029</fpage>–<lpage>1038</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2006.11.153</pub-id><pub-id pub-id-type="pmid">17316633</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Soerjomatraram</surname><given-names>I.</given-names></name><name><surname>Ervik</surname><given-names>M.</given-names></name><name><surname>Dikshit</surname><given-names>R.</given-names></name><name><surname>Eser</surname><given-names>S.</given-names></name><name><surname>Mathers</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2013</year>). <source/>GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 (Internet). <publisher-loc>Lyon</publisher-loc>: <publisher-name>International Agency for Research on Cancer</publisher-name> Available online at: <ext-link ext-link-type="uri" xlink:href="http://globocan.iarc.fr">http://globocan.iarc.fr</ext-link></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>P. A.</given-names></name><name><surname>Chander</surname><given-names>S. K.</given-names></name><name><surname>Newman</surname><given-names>S. P.</given-names></name><name><surname>Woo</surname><given-names>L. W.</given-names></name><name><surname>Sutcliffe</surname><given-names>O. B.</given-names></name><name><surname>Bubert</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2008a</year>). <article-title>A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor</article-title>. <source/>Clin. Cancer Res.
<volume>14</volume>, <fpage>6469</fpage>–<lpage>6477</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1027</pub-id><pub-id pub-id-type="pmid">18927286</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>P. A.</given-names></name><name><surname>Chander</surname><given-names>S. K.</given-names></name><name><surname>Parsons</surname><given-names>M. F.</given-names></name><name><surname>Newman</surname><given-names>S. P.</given-names></name><name><surname>Woo</surname><given-names>L. W.</given-names></name><name><surname>Potter</surname><given-names>B. V.</given-names></name><etal></etal></person-group>. (<year>2008b</year>). <article-title>Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer</article-title>. <source/>Breast Cancer Res. Treat.
<volume>111</volume>, <fpage>129</fpage>–<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1007/s10549-007-9769-3</pub-id><pub-id pub-id-type="pmid">17914670</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>P. A.</given-names></name><name><surname>Woo</surname><given-names>L. W.</given-names></name><name><surname>Potter</surname><given-names>B. V.</given-names></name><name><surname>Reed</surname><given-names>M. J.</given-names></name><name><surname>Purohit</surname><given-names>A.</given-names></name></person-group> (<year>2008c</year>). <article-title>The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer</article-title>. <source/>Endocrinology
<volume>149</volume>, <fpage>4035</fpage>–<lpage>4042</lpage>. <pub-id pub-id-type="doi">10.1210/en.2008-0223</pub-id><pub-id pub-id-type="pmid">18450955</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fournier</surname><given-names>M. A.</given-names></name><name><surname>Poirier</surname><given-names>D.</given-names></name></person-group> (<year>2009</year>). <article-title>Estrogen formation in endometrial and cervix cancer cell lines: involvement of aromatase, steroid sulfatase and 17beta-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12)</article-title>. <source/>Mol. Cell. Endocrinol.
<volume>301</volume>, <fpage>142</fpage>–<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2008.08.027</pub-id><pub-id pub-id-type="pmid">18817841</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freimuth</surname><given-names>R. R.</given-names></name><name><surname>Wiepert</surname><given-names>M.</given-names></name><name><surname>Chute</surname><given-names>C. G.</given-names></name><name><surname>Wieben</surname><given-names>E. D.</given-names></name><name><surname>Weinshilboum</surname><given-names>R. M.</given-names></name></person-group> (<year>2004</year>). <article-title>Human cytosolic sulfotransferase database mining: identification of seven novel genes and pseudogenes</article-title>. <source/>Pharmacogenomics J.
<volume>4</volume>, <fpage>54</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1038/sj.tpj.6500223</pub-id><pub-id pub-id-type="pmid">14676822</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J.</given-names></name><name><surname>Weise</surname><given-names>A. M.</given-names></name><name><surname>Falany</surname><given-names>J. L.</given-names></name><name><surname>Falany</surname><given-names>C. N.</given-names></name><name><surname>Thibodeau</surname><given-names>B. J.</given-names></name><name><surname>Miller</surname><given-names>F. R.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression</article-title>. <source/>Breast Cancer Res. Treat.
<volume>120</volume>, <fpage>35</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1007/s10549-009-0363-8</pub-id><pub-id pub-id-type="pmid">19308726</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamage</surname><given-names>N.</given-names></name><name><surname>Barnett</surname><given-names>A.</given-names></name><name><surname>Hempel</surname><given-names>N.</given-names></name><name><surname>Duggleby</surname><given-names>R. G.</given-names></name><name><surname>Windmill</surname><given-names>K. F.</given-names></name><name><surname>Martin</surname><given-names>J. L.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Human sulfotransferases and their role in chemical metabolism</article-title>. <source/>Toxicol. Sci.
<volume>90</volume>, <fpage>5</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfj061</pub-id><pub-id pub-id-type="pmid">16322073</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geese</surname><given-names>W. J.</given-names></name><name><surname>Raftogianis</surname><given-names>R. B.</given-names></name></person-group> (<year>2001</year>). <article-title>Biochemical characterization and tissue distribution of human SULT2B1</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>288</volume>, <fpage>280</fpage>–<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.2001.5746</pub-id><pub-id pub-id-type="pmid">11594786</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gelmetti</surname><given-names>C.</given-names></name><name><surname>Ruggero</surname><given-names>C.</given-names></name></person-group> (<year>2002</year>). <source/>Pediatric Dermatology and Dermatopathology: A Concise Atlas.
<publisher-loc>London</publisher-loc>: <publisher-name>T&amp;F STM</publisher-name>.</mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>D.</given-names></name></person-group> (<year>2007</year>). <article-title>Human sulfatases: a structural perspective to catalysis</article-title>. <source/>Cell. Mol. Life Sci.
<volume>64</volume>, <fpage>2013</fpage>–<lpage>2022</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-007-7175-y</pub-id><pub-id pub-id-type="pmid">17558559</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosavi</surname><given-names>R. A.</given-names></name><name><surname>Knudsen</surname><given-names>G. A.</given-names></name><name><surname>Birnbaum</surname><given-names>L. S.</given-names></name><name><surname>Pedersen</surname><given-names>L. C.</given-names></name></person-group> (<year>2013</year>). <article-title>Mimicking of estradiol binding by flame retardants and their metabolites: a crystallographic analysis</article-title>. <source/>Environ. Health Perspect.
<volume>121</volume>, <fpage>1194</fpage>–<lpage>1199</lpage>. <pub-id pub-id-type="doi">10.1289/ehp.1306902</pub-id><pub-id pub-id-type="pmid">23959441</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graziano</surname><given-names>A.</given-names></name><name><surname>Lo Monte</surname><given-names>G.</given-names></name><name><surname>Piva</surname><given-names>I.</given-names></name><name><surname>Caserta</surname><given-names>D.</given-names></name><name><surname>Karner</surname><given-names>M.</given-names></name><name><surname>Engl</surname><given-names>B.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Diagnostic findings in adenomyosis: a pictorial review on the major concerns</article-title>. <source/>Eur. Rev. Med. Pharmacol. Sci.
<volume>19</volume>, <fpage>1146</fpage>–<lpage>1154</lpage>. <pub-id pub-id-type="pmid">25912572</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarneri</surname><given-names>V.</given-names></name><name><surname>Barbieri</surname><given-names>E.</given-names></name><name><surname>Dieci</surname><given-names>M. V.</given-names></name><name><surname>Piacentini</surname><given-names>F.</given-names></name><name><surname>Conte</surname><given-names>P.</given-names></name></person-group> (<year>2011</year>). <article-title>Timing for starting second-line therapy in recurrent ovarian cancer</article-title>. <source/>Expert Rev. Anticancer Ther.
<volume>11</volume>, <fpage>49</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1586/era.10.204</pub-id><pub-id pub-id-type="pmid">21166510</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S. W.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name></person-group> (<year>2006</year>). <article-title>Sources of heterogeneities in estimating the prevalence of endometriosis in infertile and previously fertile women</article-title>. <source/>Fertil. Steril.
<volume>86</volume>, <fpage>1584</fpage>–<lpage>1595</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2006.04.040</pub-id><pub-id pub-id-type="pmid">17067588</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>B. E.</given-names></name><name><surname>Feigelson</surname><given-names>H. S.</given-names></name></person-group> (<year>2000</year>). <article-title>Hormonal carcinogenesis</article-title>. <source/>Carcinogenesis
<volume>21</volume>, <fpage>427</fpage>–<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/21.3.427</pub-id><pub-id pub-id-type="pmid">10688862</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Guzman</surname><given-names>F. G.</given-names></name><name><surname>Higashiyama</surname><given-names>T.</given-names></name><name><surname>Osawa</surname><given-names>Y.</given-names></name><name><surname>Ghosh</surname><given-names>D.</given-names></name></person-group> (<year>2001</year>). <article-title>Purification, characterization and crystallization of human placental estrone/dehydroepiandrosterone sulfatase, a membrane-bound enzyme of the endoplasmic reticulum</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>78</volume>, <fpage>441</fpage>–<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1016/S0960-0760(01)00119-4</pub-id><pub-id pub-id-type="pmid">11738554</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Guzman</surname><given-names>F. G.</given-names></name><name><surname>Higashiyama</surname><given-names>T.</given-names></name><name><surname>Pangborn</surname><given-names>W.</given-names></name><name><surname>Osawa</surname><given-names>Y.</given-names></name><name><surname>Ghosh</surname><given-names>D.</given-names></name></person-group> (<year>2003</year>). <article-title>Structure of human estrone sulfatase suggests functional roles of membrane association</article-title>. <source/>J. Biol. Chem.
<volume>278</volume>, <fpage>22989</fpage>–<lpage>22997</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M211497200</pub-id><pub-id pub-id-type="pmid">12657638</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hevir</surname><given-names>N.</given-names></name><name><surname>Ribic-Pucelj</surname><given-names>M.</given-names></name><name><surname>Lanišnik Rižner</surname><given-names>T.</given-names></name></person-group> (<year>2013</year>). <article-title>Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis: a source of excessive hydroxy-estrogens and ROS?</article-title>
<source/>Mol. Cell. Endocrinol.
<volume>367</volume>, <fpage>74</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2012.12.019</pub-id><pub-id pub-id-type="pmid">23277161</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hevir</surname><given-names>N.</given-names></name><name><surname>Sinkovec</surname><given-names>J.</given-names></name><name><surname>Rižner</surname><given-names>T. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of S-COMT</article-title>. <source/>Mol. Cell. Endocrinol.
<volume>331</volume>, <fpage>158</fpage>–<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2010.09.011</pub-id><pub-id pub-id-type="pmid">20887769</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hevir-Kene</surname><given-names>N.</given-names></name><name><surname>Rižner</surname><given-names>T. L.</given-names></name></person-group> (<year>2015</year>). <article-title>The endometrial cancer cell lines Ishikawa and HEC-1A, and the control cell line HIEEC, differ in expression of estrogen biosynthetic and metabolic genes, and in androstenedione and estrone-sulfate metabolism</article-title>. <source/>Chem. Biol. Interact.
<volume>234</volume>, <fpage>309</fpage>–<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbi.2014.11.015</pub-id><pub-id pub-id-type="pmid">25437045</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hildebrandt</surname><given-names>M. A.</given-names></name><name><surname>Carrington</surname><given-names>D. P.</given-names></name><name><surname>Thomae</surname><given-names>B. A.</given-names></name><name><surname>Eckloff</surname><given-names>B. W.</given-names></name><name><surname>Schaid</surname><given-names>D. J.</given-names></name><name><surname>Yee</surname><given-names>V. C.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Genetic diversity and function in the human cytosolic sulfotransferases</article-title>. <source/>Pharmacogenomics J.
<volume>7</volume>, <fpage>133</fpage>–<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1038/sj.tpj.6500404</pub-id><pub-id pub-id-type="pmid">16801938</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>H.</given-names></name><name><surname>Hinoda</surname><given-names>Y.</given-names></name><name><surname>Okayama</surname><given-names>N.</given-names></name><name><surname>Suehiro</surname><given-names>Y.</given-names></name><name><surname>Kawamoto</surname><given-names>K.</given-names></name><name><surname>Kikuno</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility</article-title>. <source/>Cancer
<volume>112</volume>, <fpage>1964</fpage>–<lpage>1973</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.23392</pub-id><pub-id pub-id-type="pmid">18318428</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>Y. T.</given-names></name><name><surname>Purohit</surname><given-names>A.</given-names></name><name><surname>Vicker</surname><given-names>N.</given-names></name><name><surname>Newman</surname><given-names>S. P.</given-names></name><name><surname>Robinson</surname><given-names>J. J.</given-names></name><name><surname>Leese</surname><given-names>M. P.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>305</volume>, <fpage>909</fpage>–<lpage>914</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-291X(03)00865-9</pub-id><pub-id pub-id-type="pmid">12767917</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudelist</surname><given-names>G.</given-names></name><name><surname>Czerwenka</surname><given-names>K.</given-names></name><name><surname>Keckstein</surname><given-names>J.</given-names></name><name><surname>Haas</surname><given-names>C.</given-names></name><name><surname>Fink-Retter</surname><given-names>A.</given-names></name><name><surname>Gschwantler-Kaulich</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Expression of aromatase and estrogen sulfotransferase in eutopic and ectopic endometrium: evidence for unbalanced estradiol production in endometriosis</article-title>. <source/>Reprod. Sci.
<volume>14</volume>, <fpage>798</fpage>–<lpage>805</lpage>. <pub-id pub-id-type="doi">10.1177/1933719107309120</pub-id><pub-id pub-id-type="pmid">18089598</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huhtinen</surname><given-names>K.</given-names></name><name><surname>Suvitie</surname><given-names>P.</given-names></name><name><surname>Hiissa</surname><given-names>J.</given-names></name><name><surname>Junnila</surname><given-names>J.</given-names></name><name><surname>Huvila</surname><given-names>J.</given-names></name><name><surname>Kujari</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts</article-title>. <source/>Br. J. Cancer
<volume>100</volume>, <fpage>1315</fpage>–<lpage>1319</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6605011</pub-id><pub-id pub-id-type="pmid">19337252</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Current molecular aspects of the carcinogenesis of the uterine endometrium</article-title>. <source/>Int. J. Gynecol. Cancer
<volume>11</volume>, <fpage>339</fpage>–<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1046/j.1525-1438.2001.01046.x</pub-id><pub-id pub-id-type="pmid">11737463</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>H.</given-names></name><name><surname>Nakata</surname><given-names>T.</given-names></name><name><surname>Suzuki</surname><given-names>M.</given-names></name><name><surname>Shiotsu</surname><given-names>Y.</given-names></name><name><surname>Tanaka</surname><given-names>H.</given-names></name><name><surname>Sato</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>A novel steroidal selective steroid sulfatase inhibitor KW-2581 inhibits sulfated-estrogen dependent growth of breast cancer cells <italic>in vitro</italic> and in animal models</article-title>. <source/>Breast Cancer Res. Treat.
<volume>106</volume>, <fpage>215</fpage>–<lpage>227</lpage>. <pub-id pub-id-type="doi">10.1007/s10549-007-9495-x</pub-id><pub-id pub-id-type="pmid">17268815</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jasonni</surname><given-names>V. M.</given-names></name><name><surname>Bulletti</surname><given-names>C.</given-names></name><name><surname>Franceschetti</surname><given-names>F.</given-names></name><name><surname>Bonavia</surname><given-names>M.</given-names></name><name><surname>Bolelli</surname><given-names>G.</given-names></name><name><surname>Ciotti</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>1984</year>). <article-title>Estrone sulphate plasma levels in postmenopausal women with and without endometrial cancer</article-title>. <source/>Cancer
<volume>53</volume>, <fpage>2698</fpage>–<lpage>2700</lpage>. <pub-id pub-id-type="pmid">6722729</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>L.</given-names></name><name><surname>Emerton</surname><given-names>J.</given-names></name><name><surname>Bhadravathi</surname><given-names>V.</given-names></name><name><surname>Weisblatt</surname><given-names>E.</given-names></name><name><surname>Pasco</surname><given-names>G.</given-names></name><name><surname>Willatt</surname><given-names>L. R.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>X-linked ichthyosis (steroid sulfatase deficiency) is associated with increased risk of attention deficit hyperactivity disorder, autism and social communication deficits</article-title>. <source/>J. Med. Genet.
<volume>45</volume>, <fpage>519</fpage>–<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.2008.057729</pub-id><pub-id pub-id-type="pmid">18413370</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kester</surname><given-names>M. H.</given-names></name><name><surname>Bulduk</surname><given-names>S.</given-names></name><name><surname>Tibboel</surname><given-names>D.</given-names></name><name><surname>Meinl</surname><given-names>W.</given-names></name><name><surname>Glatt</surname><given-names>H.</given-names></name><name><surname>Falany</surname><given-names>C. N.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>Potent inhibition of estrogen sulfotransferase by hydroxylated PCB metabolites: a novel pathway explaining the estrogenic activity of PCBs</article-title>. <source/>Endocrinology
<volume>141</volume>, <fpage>1897</fpage>–<lpage>1900</lpage>. <pub-id pub-id-type="doi">10.1210/endo.141.5.7530</pub-id><pub-id pub-id-type="pmid">10803601</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitawaki</surname><given-names>J.</given-names></name></person-group> (<year>2006</year>). <article-title>Adenomyosis: the pathophysiology of an oestrogen-dependent disease</article-title>. <source/>Best Pract. Res. Clin. Obstet. Gynaecol.
<volume>20</volume>, <fpage>493</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpobgyn.2006.01.010</pub-id><pub-id pub-id-type="pmid">16564227</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitawaki</surname><given-names>J.</given-names></name><name><surname>Noguchi</surname><given-names>T.</given-names></name><name><surname>Amatsu</surname><given-names>T.</given-names></name><name><surname>Maeda</surname><given-names>K.</given-names></name><name><surname>Tsukamoto</surname><given-names>K.</given-names></name><name><surname>Yamamoto</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>1997</year>). <article-title>Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium</article-title>. <source/>Biol. Reprod.
<volume>57</volume>, <fpage>514</fpage>–<lpage>519</lpage>. <pub-id pub-id-type="doi">10.1095/biolreprod57.3.514</pub-id><pub-id pub-id-type="pmid">9282984</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kästingschäfer</surname><given-names>C. S.</given-names></name><name><surname>Schäfer</surname><given-names>S. D.</given-names></name><name><surname>Kiesel</surname><given-names>L.</given-names></name><name><surname>Götte</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>miR-142-3p is a novel regulator of cell viability and proinflammatory signalling in endometrial stroma cells</article-title>. <source/>Reprod. Biomed. Online
<volume>30</volume>, <fpage>553</fpage>–<lpage>556</lpage>. <pub-id pub-id-type="doi">10.1016/j.rbmo.2015.01.002</pub-id><pub-id pub-id-type="pmid">25754227</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koizumi</surname><given-names>M.</given-names></name><name><surname>Momoeda</surname><given-names>M.</given-names></name><name><surname>Hiroi</surname><given-names>H.</given-names></name><name><surname>Hosokawa</surname><given-names>Y.</given-names></name><name><surname>Tsutsumi</surname><given-names>R.</given-names></name><name><surname>Osuga</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Expression and regulation of cholesterol sulfotransferase (SULT2B1b) in human endometrium</article-title>. <source/>Fertil. Steril.
<volume>93</volume>, <fpage>1538</fpage>–<lpage>1544</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2009.01.075</pub-id><pub-id pub-id-type="pmid">19243756</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labrie</surname><given-names>F.</given-names></name></person-group> (<year>1991</year>). <article-title>Intracrinology</article-title>. <source/>Mol. Cell. Endocrinol.
<volume>78</volume>, <fpage>C113</fpage>–<lpage>C118</lpage>. <pub-id pub-id-type="doi">10.1016/0303-7207(91)90116-A</pub-id><pub-id pub-id-type="pmid">1838082</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labrie</surname><given-names>F.</given-names></name><name><surname>Bélanger</surname><given-names>A.</given-names></name><name><surname>Bélanger</surname><given-names>P.</given-names></name><name><surname>Bérubé</surname><given-names>R.</given-names></name><name><surname>Martel</surname><given-names>C.</given-names></name><name><surname>Cusan</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>99</volume>, <fpage>182</fpage>–<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2006.02.004</pub-id><pub-id pub-id-type="pmid">16621522</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labrie</surname><given-names>F.</given-names></name><name><surname>Cusan</surname><given-names>L.</given-names></name><name><surname>Gomez</surname><given-names>J. L.</given-names></name><name><surname>Martel</surname><given-names>C.</given-names></name><name><surname>Bérubé</surname><given-names>R.</given-names></name><name><surname>Bélanger</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>113</volume>, <fpage>52</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2008.11.004</pub-id><pub-id pub-id-type="pmid">19073258</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K. A.</given-names></name><name><surname>Fuda</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>Y. C.</given-names></name><name><surname>Negishi</surname><given-names>M.</given-names></name><name><surname>Strott</surname><given-names>C. A.</given-names></name><name><surname>Pedersen</surname><given-names>L. C.</given-names></name></person-group> (<year>2003</year>). <article-title>Crystal structure of human cholesterol sulfotransferase (SULT2B1b) in the presence of pregnenolone and 3′-phosphoadenosine 5′-phosphate. Rationale for specificity differences between prototypical SULT2A1 and the SULT2BG1 isoforms</article-title>. <source/>J. Biol. Chem.
<volume>278</volume>, <fpage>44593</fpage>–<lpage>44599</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M308312200</pub-id><pub-id pub-id-type="pmid">12923182</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Ning</surname><given-names>M.</given-names></name><name><surname>Koh</surname><given-names>K. H.</given-names></name><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Jeong</surname><given-names>H.</given-names></name></person-group> (<year>2014</year>). <article-title>17β-Estradiol induces sulfotransferase 2A1 expression through estrogen receptor α</article-title>. <source/>Drug Metab. Dispos.
<volume>42</volume>, <fpage>796</fpage>–<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.113.055178</pub-id><pub-id pub-id-type="pmid">24492894</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindsay</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>L. L.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>S. F.</given-names></name></person-group> (<year>2008</year>). <article-title>Structure, function and polymorphism of human cytosolic sulfotransferases</article-title>. <source/>Curr. Drug Metab.
<volume>9</volume>, <fpage>99</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.2174/138920008783571819</pub-id><pub-id pub-id-type="pmid">18288952</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L. Y.</given-names></name><name><surname>Hsieh</surname><given-names>Y. C.</given-names></name><name><surname>Liu</surname><given-names>M. Y.</given-names></name><name><surname>Lin</surname><given-names>Y. H.</given-names></name><name><surname>Chen</surname><given-names>C. J.</given-names></name><name><surname>Yang</surname><given-names>Y. S.</given-names></name></person-group> (<year>2008</year>). <article-title>Identification and characterization of two amino acids critical for the substrate inhibition of human dehydroepiandrosterone sulfotransferase (SULT2A1)</article-title>. <source/>Mol. Pharmacol.
<volume>73</volume>, <fpage>660</fpage>–<lpage>668</lpage>. <pub-id pub-id-type="doi">10.1124/mol.107.041038</pub-id><pub-id pub-id-type="pmid">18042734</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lurie</surname><given-names>G.</given-names></name><name><surname>Wilkens</surname><given-names>L. R.</given-names></name><name><surname>Thompson</surname><given-names>P. J.</given-names></name><name><surname>Shvetsov</surname><given-names>Y. B.</given-names></name><name><surname>Matsuno</surname><given-names>R. K.</given-names></name><name><surname>Carney</surname><given-names>M. E.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium</article-title>. <source/>PLoS ONE
<volume>6</volume>:<fpage>e20703</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0020703</pub-id><pub-id pub-id-type="pmid">21673961</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luu-The</surname><given-names>V.</given-names></name><name><surname>Dufort</surname><given-names>I.</given-names></name><name><surname>Paquet</surname><given-names>N.</given-names></name><name><surname>Reimnitz</surname><given-names>G.</given-names></name><name><surname>Labrie</surname><given-names>F.</given-names></name></person-group> (<year>1995</year>). <article-title>Structural characterization and expression of the human dehydroepiandrosterone sulfotransferase gene</article-title>. <source/>DNA Cell Biol.
<volume>14</volume>, <fpage>511</fpage>–<lpage>518</lpage>. <pub-id pub-id-type="doi">10.1089/dna.1995.14.511</pub-id><pub-id pub-id-type="pmid">7598806</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lépine</surname><given-names>J.</given-names></name><name><surname>Audet-Walsh</surname><given-names>E.</given-names></name><name><surname>Grégoire</surname><given-names>J.</given-names></name><name><surname>Têtu</surname><given-names>B.</given-names></name><name><surname>Plante</surname><given-names>M.</given-names></name><name><surname>Ménard</surname><given-names>V.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways</article-title>. <source/>J. Clin. Endocrinol. Metab.
<volume>95</volume>, <fpage>2689</fpage>–<lpage>2698</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2010-2648</pub-id><pub-id pub-id-type="pmid">20371658</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lévesque</surname><given-names>E.</given-names></name><name><surname>Laverdière</surname><given-names>I.</given-names></name><name><surname>Audet-Walsh</surname><given-names>E.</given-names></name><name><surname>Caron</surname><given-names>P.</given-names></name><name><surname>Rouleau</surname><given-names>M.</given-names></name><name><surname>Fradet</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway</article-title>. <source/>Clin. Cancer Res.
<volume>20</volume>, <fpage>2971</fpage>–<lpage>2983</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-2567</pub-id><pub-id pub-id-type="pmid">24682418</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maitoko</surname><given-names>K.</given-names></name><name><surname>Sasaki</surname><given-names>H.</given-names></name></person-group> (<year>2004</year>). <article-title>Gonadotropin-releasing hormone agonist inhibits estrone sulfatase expression of cystic endometriosis in the ovary</article-title>. <source/>Fertil. Steril.
<volume>82</volume>, <fpage>322</fpage>–<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2003.12.044</pub-id><pub-id pub-id-type="pmid">15302278</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maltais</surname><given-names>R.</given-names></name><name><surname>Poirier</surname><given-names>D.</given-names></name></person-group> (<year>2011</year>). <article-title>Steroid sulfatase inhibitors: a review covering the promising 2000-2010 decade</article-title>. <source/>Steroids
<volume>76</volume>, <fpage>929</fpage>–<lpage>948</lpage>. <pub-id pub-id-type="doi">10.1016/j.steroids.2011.03.010</pub-id><pub-id pub-id-type="pmid">21458474</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>J.</given-names></name><name><surname>Ariyoshi</surname><given-names>N.</given-names></name><name><surname>Ishii</surname><given-names>I.</given-names></name><name><surname>Kitada</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>Six novel single nucleotide polymorphisms of the steroid sulfatase gene in a Japanese population</article-title>. <source/>Drug Metab. Pharmacokinet.
<volume>25</volume>, <fpage>403</fpage>–<lpage>407</lpage>. <pub-id pub-id-type="doi">10.2133/dmpk.DMPK-10-SC-027</pub-id><pub-id pub-id-type="pmid">20814163</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>J.</given-names></name><name><surname>Ariyoshi</surname><given-names>N.</given-names></name><name><surname>Ishii</surname><given-names>I.</given-names></name><name><surname>Kitada</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Functional characterization of seven single-nucleotide polymorphisms of the steroid sulfatase gene found in a Japanese population</article-title>. <source/>J. Hum. Genet.
<volume>58</volume>, <fpage>267</fpage>–<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1038/jhg.2013.12</pub-id><pub-id pub-id-type="pmid">23466819</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuoka</surname><given-names>R.</given-names></name><name><surname>Yanaihara</surname><given-names>A.</given-names></name><name><surname>Saito</surname><given-names>H.</given-names></name><name><surname>Furusawa</surname><given-names>Y.</given-names></name><name><surname>Toma</surname><given-names>Y.</given-names></name><name><surname>Shimizu</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2002</year>). <article-title>Regulation of estrogen activity in human endometrium: effect of IL-1beta on steroid sulfatase activity in human endometrial stromal cells</article-title>. <source/>Steroids
<volume>67</volume>, <fpage>655</fpage>–<lpage>659</lpage>. <pub-id pub-id-type="doi">10.1016/S0039-128X(02)00016-8</pub-id><pub-id pub-id-type="pmid">11996939</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meloche</surname><given-names>C. A.</given-names></name><name><surname>Falany</surname><given-names>C. N.</given-names></name></person-group> (<year>2001</year>). <article-title>Expression and characterization of the human 3 beta-hydroxysteroid sulfotransferases (SULT2B1a and SULT2B1b)</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>77</volume>, <fpage>261</fpage>–<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1016/S0960-0760(01)00064-4</pub-id><pub-id pub-id-type="pmid">11457664</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modugno</surname><given-names>F.</given-names></name><name><surname>Laskey</surname><given-names>R.</given-names></name><name><surname>Smith</surname><given-names>A. L.</given-names></name><name><surname>Andersen</surname><given-names>C. L.</given-names></name><name><surname>Haluska</surname><given-names>P.</given-names></name><name><surname>Oesterreich</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>). <article-title>Hormone response in ovarian cancer: time to reconsider as a clinical target?</article-title>
<source/>Endocr. Relat. Cancer
<volume>19</volume>, <fpage>R255</fpage>–<lpage>R279</lpage>. <pub-id pub-id-type="doi">10.1530/ERC-12-0175</pub-id><pub-id pub-id-type="pmid">23045324</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moravek</surname><given-names>M. B.</given-names></name><name><surname>Yin</surname><given-names>P.</given-names></name><name><surname>Ono</surname><given-names>M.</given-names></name><name><surname>Coon</surname><given-names>J. S.</given-names></name><name><surname>Dyson</surname><given-names>M. T.</given-names></name><name><surname>Navarro</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications</article-title>. <source/>Hum. Reprod. Update
<volume>21</volume>, <fpage>1</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1093/humupd/dmu048</pub-id><pub-id pub-id-type="pmid">25205766</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafa</surname><given-names>Y. A.</given-names></name><name><surname>Taylor</surname><given-names>S. D.</given-names></name></person-group> (<year>2013</year>). <article-title>Steroid derivatives as inhibitors of steroid sulfatase</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>137</volume>, <fpage>183</fpage>–<lpage>198</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2013.01.013</pub-id><pub-id pub-id-type="pmid">23391659</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>J. W.</given-names></name><name><surname>Gilligan</surname><given-names>L. C.</given-names></name><name><surname>Idkowiak</surname><given-names>J.</given-names></name><name><surname>Arlt</surname><given-names>W.</given-names></name><name><surname>Foster</surname><given-names>P. A.</given-names></name></person-group> (<year>2015</year>). <article-title>The regulation of steroid action by sulfation and desulfation</article-title>. <source/>Endocr. Rev.
<volume>36</volume>, <fpage>526</fpage>–<lpage>563</lpage>. <pub-id pub-id-type="doi">10.1210/er.2015-1036</pub-id><pub-id pub-id-type="pmid">26213785</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>K.</given-names></name><name><surname>Yamazoe</surname><given-names>Y.</given-names></name></person-group> (<year>2000</year>). <article-title>Pharmacogenetics of sulfotransferase</article-title>. <source/>Annu. Rev. Pharmacol. Toxicol.
<volume>40</volume>, <fpage>159</fpage>–<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.pharmtox.40.1.159</pub-id><pub-id pub-id-type="pmid">10836131</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naitoh</surname><given-names>K.</given-names></name><name><surname>Honjo</surname><given-names>H.</given-names></name><name><surname>Yamamoto</surname><given-names>T.</given-names></name><name><surname>Urabe</surname><given-names>M.</given-names></name><name><surname>Ogino</surname><given-names>Y.</given-names></name><name><surname>Yasumura</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>1989</year>). <article-title>Estrone sulfate and sulfatase activity in human breast cancer and endometrial cancer</article-title>. <source/>J. Steroid Biochem.
<volume>33</volume>, <fpage>1049</fpage>–<lpage>1054</lpage>. <pub-id pub-id-type="doi">10.1016/0022-4731(89)90408-1</pub-id><pub-id pub-id-type="pmid">2559248</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nardi</surname><given-names>A.</given-names></name><name><surname>Pomari</surname><given-names>E.</given-names></name><name><surname>Zambon</surname><given-names>D.</given-names></name><name><surname>Belvedere</surname><given-names>P.</given-names></name><name><surname>Colombo</surname><given-names>L.</given-names></name><name><surname>Dalla Valle</surname><given-names>L.</given-names></name></person-group> (<year>2009</year>). <article-title>Transcriptional control of human steroid sulfatase</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>115</volume>, <fpage>68</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2009.02.017</pub-id><pub-id pub-id-type="pmid">19429462</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negishi</surname><given-names>M.</given-names></name><name><surname>Pedersen</surname><given-names>L. G.</given-names></name><name><surname>Petrotchenko</surname><given-names>E.</given-names></name><name><surname>Shevtsov</surname><given-names>S.</given-names></name><name><surname>Gorokhov</surname><given-names>A.</given-names></name><name><surname>Kakuta</surname><given-names>Y.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>Structure and function of sulfotransferases</article-title>. <source/>Arch. Biochem. Biophys.
<volume>390</volume>, <fpage>149</fpage>–<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1006/abbi.2001.2368</pub-id><pub-id pub-id-type="pmid">11396917</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>S. P.</given-names></name><name><surname>Purohit</surname><given-names>A.</given-names></name><name><surname>Ghilchik</surname><given-names>M. W.</given-names></name><name><surname>Potter</surname><given-names>B. V.</given-names></name><name><surname>Reed</surname><given-names>M. J.</given-names></name></person-group> (<year>2000</year>). <article-title>Regulation of steroid sulphatase expression and activity in breast cancer</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>75</volume>, <fpage>259</fpage>–<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1016/S0960-0760(00)00177-1</pub-id><pub-id pub-id-type="pmid">11282280</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname><given-names>T.</given-names></name><name><surname>Saito</surname><given-names>H.</given-names></name><name><surname>Sekizawa</surname><given-names>A.</given-names></name><name><surname>Shimizu</surname><given-names>Y.</given-names></name><name><surname>Akamatsu</surname><given-names>T.</given-names></name><name><surname>Kushima</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>Steroid sulfatase expression in ovarian clear cell adenocarcinoma: immunohistochemical study</article-title>. <source/>Gynecol. Oncol.
<volume>82</volume>, <fpage>427</fpage>–<lpage>434</lpage>. <pub-id pub-id-type="doi">10.1006/gyno.2001.6322</pub-id><pub-id pub-id-type="pmid">11520136</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqualini</surname><given-names>J. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Estrogen sulfotransferases in breast and endometrial cancers</article-title>. <source/>Ann. N.Y. Acad. Sci.
<volume>1155</volume>, <fpage>88</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2009.04113.x</pub-id><pub-id pub-id-type="pmid">19250196</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqualini</surname><given-names>J. R.</given-names></name><name><surname>Chetrite</surname><given-names>G.</given-names></name><name><surname>Nestour</surname><given-names>E. L.</given-names></name></person-group> (<year>1996</year>). <article-title>Control and expression of oestrone sulphatase activities in human breast cancer</article-title>. <source/>J. Endocrinol.
<volume>150</volume>(<issue>Suppl.</issue>), <fpage>S99</fpage>–<lpage>S105</lpage>. <pub-id pub-id-type="pmid">8943793</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasqualini</surname><given-names>J. R.</given-names></name><name><surname>Cornier</surname><given-names>E.</given-names></name><name><surname>Grenier</surname><given-names>J.</given-names></name><name><surname>Vella</surname><given-names>C.</given-names></name><name><surname>Schatz</surname><given-names>B.</given-names></name><name><surname>Netter</surname><given-names>A.</given-names></name></person-group> (<year>1990</year>). <article-title>Effect of decapeptyl (D-TrpG GnPh) on estrogen receptors, progesterone receptors and tissue levels of estrogens (non-conjugated and sulfate-conjugated) in patients with uterine myoma</article-title>. <source/>Pathol. Biol.
<volume>38</volume>, <fpage>941</fpage>–<lpage>943</lpage>. <pub-id pub-id-type="pmid">2148976</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pautier</surname><given-names>P.</given-names></name><name><surname>Lobbedez</surname><given-names>F.</given-names></name><name><surname>Melchar</surname><given-names>B.</given-names></name><name><surname>Kutarska</surname><given-names>E.</given-names></name><name><surname>Hall</surname><given-names>G.</given-names></name><name><surname>Reed</surname><given-names>N.</given-names></name></person-group> (<year>2012</year>). <article-title>A phase II multicentre randomized open-label study of oral steroid sulphatase (STS) inhibitor irosustat (BN83495) versus megestrol acetate (MA) in women with advanced/recurrent endometrial cancer</article-title>. <source/>Annals Oncol. <volume>23</volume>(<issue>suppl. 9</issue>), <fpage>329</fpage>.</mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>L. C.</given-names></name><name><surname>Petrotchenko</surname><given-names>E.</given-names></name><name><surname>Shevtsov</surname><given-names>S.</given-names></name><name><surname>Negishi</surname><given-names>M.</given-names></name></person-group> (<year>2002</year>). <article-title>Crystal structure of the human estrogen sulfotransferase-PAPS complex: evidence for catalytic role of Ser137 in the sulfuryl transfer reaction</article-title>. <source/>J. Biol. Chem.
<volume>277</volume>, <fpage>17928</fpage>–<lpage>17932</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111651200</pub-id><pub-id pub-id-type="pmid">11884392</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pohl</surname><given-names>O.</given-names></name><name><surname>Bestel</surname><given-names>E.</given-names></name><name><surname>Gotteland</surname><given-names>J. P.</given-names></name></person-group> (<year>2014</year>). <article-title>Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age</article-title>. <source/>Reprod. Sci.
<volume>21</volume>, <fpage>1256</fpage>–<lpage>1265</lpage>. <pub-id pub-id-type="doi">10.1177/1933719114522526</pub-id><pub-id pub-id-type="pmid">24604234</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poirier</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>Recent patents on new steroid agents targeting the steroidogenesis for endocrine cancer treatments</article-title>. <source/>Recent Pat. Endocr. Metab. Immune Drug Discov.
<volume>9</volume>, <fpage>15</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.2174/1872214809666150201214602</pub-id><pub-id pub-id-type="pmid">25643356</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preusser-Kunze</surname><given-names>A.</given-names></name><name><surname>Mariappan</surname><given-names>M.</given-names></name><name><surname>Schmidt</surname><given-names>B.</given-names></name><name><surname>Gande</surname><given-names>S. L.</given-names></name><name><surname>Mutenda</surname><given-names>K.</given-names></name><name><surname>Wenzel</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Molecular characterization of the human Calpha-formylglycine-generating enzyme</article-title>. <source/>J. Biol. Chem.
<volume>280</volume>, <fpage>14900</fpage>–<lpage>14910</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M413383200</pub-id><pub-id pub-id-type="pmid">15657036</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prost</surname><given-names>O.</given-names></name><name><surname>Turrel</surname><given-names>M. O.</given-names></name><name><surname>Dahan</surname><given-names>N.</given-names></name><name><surname>Craveur</surname><given-names>C.</given-names></name><name><surname>Adessi</surname><given-names>G. L.</given-names></name></person-group> (<year>1984</year>). <article-title>Estrone and dehydroepiandrosterone sulfatase activities and plasma estrone sulfate levels in human breast carcinoma</article-title>. <source/>Cancer Res.
<volume>44</volume>, <fpage>661</fpage>–<lpage>664</lpage>. <pub-id pub-id-type="pmid">6581863</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purohit</surname><given-names>A.</given-names></name><name><surname>Fusi</surname><given-names>L.</given-names></name><name><surname>Brosens</surname><given-names>J.</given-names></name><name><surname>Woo</surname><given-names>L. W.</given-names></name><name><surname>Potter</surname><given-names>B. V.</given-names></name><name><surname>Reed</surname><given-names>M. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy</article-title>. <source/>Hum. Reprod.
<volume>23</volume>, <fpage>290</fpage>–<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1093/humrep/dem308</pub-id><pub-id pub-id-type="pmid">18056119</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purohit</surname><given-names>A.</given-names></name><name><surname>Potter</surname><given-names>B. V.</given-names></name><name><surname>Parker</surname><given-names>M. G.</given-names></name><name><surname>Reed</surname><given-names>M. J.</given-names></name></person-group> (<year>1998</year>). <article-title>Steroid sulphatase: expression, isolation and inhibition for active-site identification studies</article-title>. <source/>Chem. Biol. Interact.
<volume>109</volume>, <fpage>183</fpage>–<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/S0009-2797(97)00132-4</pub-id><pub-id pub-id-type="pmid">9566745</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purohit</surname><given-names>A.</given-names></name><name><surname>Woo</surname><given-names>L. W.</given-names></name><name><surname>Potter</surname><given-names>B. V.</given-names></name></person-group> (<year>2011</year>). <article-title>Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism</article-title>. <source/>Mol. Cell. Endocrinol.
<volume>340</volume>, <fpage>154</fpage>–<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2011.06.012</pub-id><pub-id pub-id-type="pmid">21693170</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raftogianis</surname><given-names>R.</given-names></name><name><surname>Creveling</surname><given-names>C.</given-names></name><name><surname>Weinshilboum</surname><given-names>R.</given-names></name><name><surname>Weisz</surname><given-names>J.</given-names></name></person-group> (<year>2000</year>). <article-title>Estrogen metabolism by conjugation</article-title>. <source/>J. Natl. Cancer Inst. Monogr.
<volume>27</volume>, <fpage>113</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.jncimonographs.a024234</pub-id><pub-id pub-id-type="pmid">10963623</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>L. M.</given-names></name><name><surname>Zaveri</surname><given-names>N. T.</given-names></name><name><surname>Stenvang</surname><given-names>J.</given-names></name><name><surname>Peters</surname><given-names>R. H.</given-names></name><name><surname>Lykkesfeldt</surname><given-names>A. E.</given-names></name></person-group> (<year>2007</year>). <article-title>A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer</article-title>. <source/>Breast Cancer Res. Treat.
<volume>106</volume>, <fpage>191</fpage>–<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1007/s10549-007-9494-y</pub-id><pub-id pub-id-type="pmid">17268816</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebbeck</surname><given-names>T. R.</given-names></name><name><surname>Troxel</surname><given-names>A. B.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Walker</surname><given-names>A. H.</given-names></name><name><surname>Panossian</surname><given-names>S.</given-names></name><name><surname>Gallagher</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk</article-title>. <source/>J. Natl. Cancer Inst.
<volume>98</volume>, <fpage>1311</fpage>–<lpage>1320</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djj360</pub-id><pub-id pub-id-type="pmid">16985250</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>M. J.</given-names></name><name><surname>Purohit</surname><given-names>A.</given-names></name><name><surname>Woo</surname><given-names>L. W.</given-names></name><name><surname>Newman</surname><given-names>S. P.</given-names></name><name><surname>Potter</surname><given-names>B. V.</given-names></name></person-group> (<year>2005</year>). <article-title>Steroid sulfatase: molecular biology, regulation, and inhibition</article-title>. <source/>Endocr. Rev.
<volume>26</volume>, <fpage>171</fpage>–<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1210/er.2004-0003</pub-id><pub-id pub-id-type="pmid">15561802</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rehse</surname><given-names>P. H.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Lin</surname><given-names>S. X.</given-names></name></person-group> (<year>2002</year>). <article-title>Crystal structure of human dehydroepiandrosterone sulphotransferase in complex with substrate</article-title>. <source/>Biochem. J. <volume>364</volume>(<issue>Pt 1</issue>), <fpage>165</fpage>–<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1042/bj3640165</pub-id><pub-id pub-id-type="pmid">11988089</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Hillier</surname><given-names>S. G.</given-names></name><name><surname>Fegan</surname><given-names>K. S.</given-names></name><name><surname>Critchley</surname><given-names>H. O.</given-names></name><name><surname>Mason</surname><given-names>J. I.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Local estrogen metabolism in epithelial ovarian cancer suggests novel targets for therapy</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>150</volume>, <fpage>54</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2015.03.010</pub-id><pub-id pub-id-type="pmid">25817828</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rižner</surname><given-names>T. L.</given-names></name></person-group> (<year>2009</year>). <article-title>Estrogen metabolism and action in endometriosis</article-title>. <source/>Mol. Cell. Endocrinol.
<volume>307</volume>, <fpage>8</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2009.03.022</pub-id><pub-id pub-id-type="pmid">19524121</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rižner</surname><given-names>T. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer</article-title>. <source/>Mol. Cell. Endocrinol.
<volume>381</volume>, <fpage>124</fpage>–<lpage>139</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2013.07.026</pub-id><pub-id pub-id-type="pmid">23911898</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>P. A.</given-names></name><name><surname>D'Hooghe</surname><given-names>T. M.</given-names></name><name><surname>Fazleabas</surname><given-names>A.</given-names></name><name><surname>Giudice</surname><given-names>L. C.</given-names></name><name><surname>Montgomery</surname><given-names>G. W.</given-names></name><name><surname>Petraglia</surname><given-names>F.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Defining future directions for endometriosis research: workshop report from the 2011 World Congress of Endometriosis In Montpellier, France</article-title>. <source/>Reprod. Sci.
<volume>20</volume>, <fpage>483</fpage>–<lpage>499</lpage>. <pub-id pub-id-type="doi">10.1177/1933719113477495</pub-id><pub-id pub-id-type="pmid">23427182</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>G. L.</given-names></name><name><surname>Harrold</surname><given-names>A. J.</given-names></name><name><surname>Mills</surname><given-names>J. A.</given-names></name><name><surname>Falany</surname><given-names>C. N.</given-names></name><name><surname>Coughtrie</surname><given-names>M. W.</given-names></name></person-group> (<year>1999</year>). <article-title>Regulation of sulphotransferase expression in the endometrium during the menstrual cycle, by oral contraceptives and during early pregnancy</article-title>. <source/>Mol. Hum. Reprod.
<volume>5</volume>, <fpage>995</fpage>–<lpage>1002</lpage>. <pub-id pub-id-type="doi">10.1093/molehr/5.11.995</pub-id><pub-id pub-id-type="pmid">10541560</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>A. J.</given-names></name><name><surname>Susil</surname><given-names>B.</given-names></name><name><surname>Jobling</surname><given-names>T. W.</given-names></name><name><surname>Oehler</surname><given-names>M. K.</given-names></name></person-group> (<year>2005</year>). <article-title>Endometrial cancer</article-title>. <source/>Cell Tissue Res.
<volume>322</volume>, <fpage>53</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1007/s00441-005-1109-5</pub-id><pub-id pub-id-type="pmid">15947972</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadozai</surname><given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>Steroid sulfatase inhibitors: promising new therapy for breast cancer</article-title>. <source/>J. Pak. Med. Assoc.
<volume>63</volume>, <fpage>509</fpage>–<lpage>515</lpage>. <pub-id pub-id-type="pmid">23905452</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saner</surname><given-names>K. J.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Sasano</surname><given-names>H.</given-names></name><name><surname>Pizzey</surname><given-names>J.</given-names></name><name><surname>Ho</surname><given-names>C.</given-names></name><name><surname>Strauss</surname><given-names>J. F.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Steroid sulfotransferase 2A1 gene transcription is regulated by steroidogenic factor 1 and GATA-6 in the human adrenal</article-title>. <source/>Mol. Endocrinol.
<volume>19</volume>, <fpage>184</fpage>–<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1210/me.2003-0332</pub-id><pub-id pub-id-type="pmid">15388788</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>Y. K.</given-names></name><name><surname>Mirkheshti</surname><given-names>N.</given-names></name><name><surname>Song</surname><given-names>C. S.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Dodds</surname><given-names>S.</given-names></name><name><surname>Ahn</surname><given-names>S. C.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer</article-title>. <source/>Mol. Endocrinol.
<volume>27</volume>, <fpage>925</fpage>–<lpage>939</lpage>. <pub-id pub-id-type="doi">10.1210/me.2012-1369</pub-id><pub-id pub-id-type="pmid">23579488</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>E. R.</given-names></name></person-group> (<year>2003</year>). <article-title>Sources of estrogen and their importance</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>86</volume>, <fpage>225</fpage>–<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1016/S0960-0760(03)00360-1</pub-id><pub-id pub-id-type="pmid">14623515</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smuc</surname><given-names>T.</given-names></name><name><surname>Hevir</surname><given-names>N.</given-names></name><name><surname>Ribic-Pucelj</surname><given-names>M.</given-names></name><name><surname>Husen</surname><given-names>B.</given-names></name><name><surname>Thole</surname><given-names>H.</given-names></name><name><surname>Rizner</surname><given-names>T. L.</given-names></name></person-group> (<year>2009</year>). <article-title>Disturbed estrogen and progesterone action in ovarian endometriosis</article-title>. <source/>Mol. Cell. Endocrinol.
<volume>301</volume>, <fpage>59</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2008.07.020</pub-id><pub-id pub-id-type="pmid">18762229</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smuc</surname><given-names>T.</given-names></name><name><surname>Pucelj</surname><given-names>M. R.</given-names></name><name><surname>Sinkovec</surname><given-names>J.</given-names></name><name><surname>Husen</surname><given-names>B.</given-names></name><name><surname>Thole</surname><given-names>H.</given-names></name><name><surname>Lanisnik Rizner</surname><given-names>T.</given-names></name></person-group> (<year>2007</year>). <article-title>Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis</article-title>. <source/>Gynecol. Endocrinol.
<volume>23</volume>, <fpage>105</fpage>–<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1080/09513590601152219</pub-id><pub-id pub-id-type="pmid">17454161</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smuc</surname><given-names>T.</given-names></name><name><surname>Rizner</surname><given-names>T. L.</given-names></name></person-group> (<year>2009</year>). <article-title>Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer</article-title>. <source/>Mol. Cell. Endocrinol.
<volume>301</volume>, <fpage>74</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2008.09.019</pub-id><pub-id pub-id-type="pmid">18930784</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonoda</surname><given-names>Y.</given-names></name><name><surname>Barakat</surname><given-names>R. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Screening and the prevention of gynecologic cancer: endometrial cancer</article-title>. <source/>Best Pract. Res. Clin. Obstet. Gynaecol.
<volume>20</volume>, <fpage>363</fpage>–<lpage>377</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpobgyn.2005.10.015</pub-id><pub-id pub-id-type="pmid">16364689</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadel</surname><given-names>B. V.</given-names></name></person-group> (<year>1975</year>). <article-title>Letter: the etiology and prevention of ovarian cancer</article-title>. <source/>Am. J. Obstet. Gynecol.
<volume>123</volume>, <fpage>772</fpage>–<lpage>774</lpage>. <pub-id pub-id-type="pmid">1200073</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanway</surname><given-names>S. J.</given-names></name><name><surname>Purohit</surname><given-names>A.</given-names></name><name><surname>Woo</surname><given-names>L. W.</given-names></name><name><surname>Sufi</surname><given-names>S.</given-names></name><name><surname>Vigushin</surname><given-names>D.</given-names></name><name><surname>Ward</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor</article-title>. <source/>Clin. Cancer Res.
<volume>12</volume>, <fpage>1585</fpage>–<lpage>1592</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1996</pub-id><pub-id pub-id-type="pmid">16533785</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stergiakouli</surname><given-names>E.</given-names></name><name><surname>Langley</surname><given-names>K.</given-names></name><name><surname>Williams</surname><given-names>H.</given-names></name><name><surname>Walters</surname><given-names>J.</given-names></name><name><surname>Williams</surname><given-names>N. M.</given-names></name><name><surname>Suren</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Steroid sulfatase is a potential modifier of cognition in attention deficit hyperactivity disorder</article-title>. <source/>Genes Brain Behav.
<volume>10</volume>, <fpage>334</fpage>–<lpage>344</lpage>. <pub-id pub-id-type="doi">10.1111/j.1601-183X.2010.00672.x</pub-id><pub-id pub-id-type="pmid">21255266</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>C. H.</given-names></name><name><surname>Im</surname><given-names>H. J.</given-names></name><name><surname>Park</surname><given-names>N.</given-names></name><name><surname>Kwon</surname><given-names>Y.</given-names></name><name><surname>Shin</surname><given-names>S.</given-names></name><name><surname>Ye</surname><given-names>D. J.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Induction of steroid sulfatase expression in PC-3 human prostate cancer cells by insulin-like growth factor II</article-title>. <source/>Toxicol. Lett.
<volume>223</volume>, <fpage>109</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/j.toxlet.2013.09.006</pub-id><pub-id pub-id-type="pmid">24055520</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>K.</given-names></name><name><surname>Kubushiro</surname><given-names>K.</given-names></name><name><surname>Iwamori</surname><given-names>Y.</given-names></name><name><surname>Okairi</surname><given-names>Y.</given-names></name><name><surname>Kiguchi</surname><given-names>K.</given-names></name><name><surname>Ishiwata</surname><given-names>I.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>Estrogen sulfotransferase and sulfatase: roles in the regulation of estrogen activity in human uterine endometrial carcinomas</article-title>. <source/>Cancer Sci.
<volume>94</volume>, <fpage>871</fpage>–<lpage>876</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.2003.tb01369.x</pub-id><pub-id pub-id-type="pmid">14556660</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomae</surname><given-names>B. A.</given-names></name><name><surname>Eckloff</surname><given-names>B. W.</given-names></name><name><surname>Freimuth</surname><given-names>R. R.</given-names></name><name><surname>Wieben</surname><given-names>E. D.</given-names></name><name><surname>Weinshilboum</surname><given-names>R. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Human sulfotransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies</article-title>. <source/>Pharmacogenomics J.
<volume>2</volume>, <fpage>48</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1038/sj.tpj.6500089</pub-id><pub-id pub-id-type="pmid">11990382</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>M. P.</given-names></name><name><surname>Potter</surname><given-names>B. V.</given-names></name></person-group> (<year>2013</year>). <article-title>The structural biology of oestrogen metabolism</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>137</volume>, <fpage>27</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2012.12.014</pub-id><pub-id pub-id-type="pmid">23291110</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>M. P.</given-names></name><name><surname>Potter</surname><given-names>B. V.</given-names></name></person-group> (<year>2015</year>). <article-title>Estrogen O-sulfamates and their analogues: clinical steroid sulfatase inhibitors with broad potential</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>153</volume>, <fpage>160</fpage>–<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2015.03.012</pub-id><pub-id pub-id-type="pmid">25843211</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibbs</surname><given-names>Z. E.</given-names></name><name><surname>Rohn-Glowacki</surname><given-names>K. J.</given-names></name><name><surname>Crittenden</surname><given-names>F.</given-names></name><name><surname>Guidry</surname><given-names>A. L.</given-names></name><name><surname>Falany</surname><given-names>C. N.</given-names></name></person-group> (<year>2015</year>). <article-title>Structural plasticity in the human cytosolic sulfotransferase dimer and its role in substrate selectivity and catalysis</article-title>. <source/>Drug Metab. Pharmacokinet.
<volume>30</volume>, <fpage>3</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.dmpk.2014.10.004</pub-id><pub-id pub-id-type="pmid">25760527</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>L.</given-names></name><name><surname>Mazella</surname><given-names>J.</given-names></name><name><surname>Mann</surname><given-names>W. J.</given-names></name><name><surname>Chumas</surname><given-names>J.</given-names></name></person-group> (<year>1982</year>). <article-title>Estrogen synthesis in normal and malignant human endometrium</article-title>. <source/>J. Clin. Endocrinol. Metab.
<volume>55</volume>, <fpage>1029</fpage>–<lpage>1031</lpage>. <pub-id pub-id-type="doi">10.1210/jcem-55-5-1029</pub-id><pub-id pub-id-type="pmid">7119084</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tworoger</surname><given-names>S. S.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Eliassen</surname><given-names>A. H.</given-names></name><name><surname>Qian</surname><given-names>J.</given-names></name><name><surname>Colditz</surname><given-names>G. A.</given-names></name><name><surname>Willett</surname><given-names>W. C.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer</article-title>. <source/>J. Clin. Oncol.
<volume>32</volume>, <fpage>3111</fpage>–<lpage>3117</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2014.56.1068</pub-id><pub-id pub-id-type="pmid">25135988</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlén</surname><given-names>M.</given-names></name><name><surname>Fagerberg</surname><given-names>L.</given-names></name><name><surname>Hallström</surname><given-names>B. M.</given-names></name><name><surname>Lindskog</surname><given-names>C.</given-names></name><name><surname>Oksvold</surname><given-names>P.</given-names></name><name><surname>Mardinoglu</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2015</year>). <article-title>Proteomics. Tissue-based map of the human proteome</article-title>. <source/>Science
<volume>347</volume>:<fpage>1260419</fpage>. <pub-id pub-id-type="doi">10.1126/science.1260419</pub-id><pub-id pub-id-type="pmid">25613900</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urabe</surname><given-names>M.</given-names></name><name><surname>Yamamoto</surname><given-names>T.</given-names></name><name><surname>Naitoh</surname><given-names>K.</given-names></name><name><surname>Honjo</surname><given-names>H.</given-names></name><name><surname>Okada</surname><given-names>H.</given-names></name></person-group> (<year>1989</year>). <article-title>Estrone sulfatase activity in normal and neoplastic endometrial tissues of human uterus</article-title>. <source/>Asia Oceania J. Obstet. Gynaecol.
<volume>15</volume>, <fpage>101</fpage>–<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1111/j.1447-0756.1989.tb00160.x</pub-id><pub-id pub-id-type="pmid">2525375</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utsunomiya</surname><given-names>H.</given-names></name><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Kitamura</surname><given-names>T.</given-names></name><name><surname>Kaneko</surname><given-names>C.</given-names></name><name><surname>Nakata</surname><given-names>T.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma</article-title>. <source/>Clin. Cancer Res.
<volume>10</volume>, <fpage>5850</fpage>–<lpage>5856</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-0040</pub-id><pub-id pub-id-type="pmid">15355916</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Ven</surname><given-names>J.</given-names></name><name><surname>Donker</surname><given-names>T. H.</given-names></name><name><surname>Blankenstein</surname><given-names>M. A.</given-names></name><name><surname>Thijssen</surname><given-names>J. H.</given-names></name></person-group> (<year>2002</year>). <article-title>Differential effect of gonadotropin-releasing hormone analogue treatment on estrogen levels and sulfatase activity in uterine leiomyoma and myometrium</article-title>. <source/>Fertil. Steril.
<volume>77</volume>, <fpage>1227</fpage>–<lpage>1232</lpage>. <pub-id pub-id-type="doi">10.1016/S0015-0282(02)03093-5</pub-id><pub-id pub-id-type="pmid">12057733</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaughan</surname><given-names>S.</given-names></name><name><surname>Coward</surname><given-names>J. I.</given-names></name><name><surname>Bast</surname><given-names>R. C.</given-names></name><name><surname>Berchuck</surname><given-names>A.</given-names></name><name><surname>Berek</surname><given-names>J. S.</given-names></name><name><surname>Brenton</surname><given-names>J. D.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Rethinking ovarian cancer: recommendations for improving outcomes</article-title>. <source/>Nat. Rev. Cancer
<volume>11</volume>, <fpage>719</fpage>–<lpage>725</lpage>. <pub-id pub-id-type="doi">10.1038/nrc3144</pub-id><pub-id pub-id-type="pmid">21941283</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Cook</surname><given-names>I.</given-names></name><name><surname>Falany</surname><given-names>C. N.</given-names></name><name><surname>Leyh</surname><given-names>T. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Paradigms of sulfotransferase catalysis: the mechanism of SULT2A1</article-title>. <source/>J. Biol. Chem.
<volume>289</volume>, <fpage>26474</fpage>–<lpage>26480</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.573501</pub-id><pub-id pub-id-type="pmid">25056952</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>S. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Sulfatase inhibitors: a patent review</article-title>. <source/>Expert Opin. Ther. Pat.
<volume>23</volume>, <fpage>79</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1517/13543776.2013.736965</pub-id><pub-id pub-id-type="pmid">23136854</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>L. L.</given-names></name><name><surname>Purohit</surname><given-names>A.</given-names></name><name><surname>Malini</surname><given-names>B.</given-names></name><name><surname>Reed</surname><given-names>M. J.</given-names></name><name><surname>Potter</surname><given-names>B. V.</given-names></name></person-group> (<year>2000</year>). <article-title>Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates</article-title>. <source/>Chem. Biol.
<volume>7</volume>, <fpage>773</fpage>–<lpage>791</lpage>. <pub-id pub-id-type="doi">10.1016/S1074-5521(00)00023-5</pub-id><pub-id pub-id-type="pmid">11033081</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Ning</surname><given-names>Y.</given-names></name><name><surname>Zhi</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Effect of estrogen sulfation by SULT1E1 and PAPSS on the development of estrogen-dependent cancers</article-title>. <source/>Cancer Sci.
<volume>103</volume>, <fpage>1000</fpage>–<lpage>1009</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.2012.02258.x</pub-id><pub-id pub-id-type="pmid">22380844</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T.</given-names></name><name><surname>Noguchi</surname><given-names>T.</given-names></name><name><surname>Tamura</surname><given-names>T.</given-names></name><name><surname>Kitawaki</surname><given-names>J.</given-names></name><name><surname>Okada</surname><given-names>H.</given-names></name></person-group> (<year>1993</year>). <article-title>Evidence for estrogen synthesis in adenomyotic tissues</article-title>. <source/>Am. J. Obstet. Gynecol.
<volume>169</volume>, <fpage>734</fpage>–<lpage>738</lpage>. <pub-id pub-id-type="doi">10.1016/0002-9378(93)90654-2</pub-id><pub-id pub-id-type="pmid">8372890</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T.</given-names></name><name><surname>Urabe</surname><given-names>M.</given-names></name><name><surname>Naitoh</surname><given-names>K.</given-names></name><name><surname>Kitawaki</surname><given-names>J.</given-names></name><name><surname>Honjo</surname><given-names>H.</given-names></name><name><surname>Okada</surname><given-names>H.</given-names></name></person-group> (<year>1990</year>). <article-title>Estrone sulfatase activity in human uterine leiomyoma</article-title>. <source/>Gynecol. Oncol.
<volume>37</volume>, <fpage>315</fpage>–<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1016/0090-8258(90)90358-R</pub-id><pub-id pub-id-type="pmid">2351313</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeramian</surname><given-names>A.</given-names></name><name><surname>Moreno-Bueno</surname><given-names>G.</given-names></name><name><surname>Dolcet</surname><given-names>X.</given-names></name><name><surname>Catasus</surname><given-names>L.</given-names></name><name><surname>Abal</surname><given-names>M.</given-names></name><name><surname>Colas</surname><given-names>E.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Endometrial carcinoma: molecular alterations involved in tumor development and progression</article-title>. <source/>Oncogene
<volume>32</volume>, <fpage>403</fpage>–<lpage>413</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2012.76</pub-id><pub-id pub-id-type="pmid">22430211</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaichuk</surname><given-names>T.</given-names></name><name><surname>Ivancic</surname><given-names>D.</given-names></name><name><surname>Scholtens</surname><given-names>D.</given-names></name><name><surname>Schiller</surname><given-names>C.</given-names></name><name><surname>Khan</surname><given-names>S. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Tissue-specific transcripts of human steroid sulfatase are under control of estrogen signaling pathways in breast carcinoma</article-title>. <source/>J. Steroid Biochem. Mol. Biol.
<volume>105</volume>, <fpage>76</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2006.12.101</pub-id><pub-id pub-id-type="pmid">17596930</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>